drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00317 | DB00794 | 883 | 759 | [
"DDInter810",
"DDInter1521"
] | Gefitinib | Primidone | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
883,
24,
759
]
],
[
[
883,
24,
697
],
[
697,
40,
759
]
],
[
[
883,
63,
362
],
[
362,
1,
759
]
],
[
[
883,
6,
6017
],
[
6017,
45,
759
]
],
[
[
883,
21,
28847
],
[
28847,
60,
759
]
],
[
[
883,
24,
752
],
[
752,
23,
759
]
],
[
[
883,
63,
1101
],
[
1101,
23,
759
]
],
[
[
883,
40,
26
],
[
26,
63,
759
]
],
[
[
883,
24,
723
],
[
723,
24,
759
]
],
[
[
883,
24,
1320
],
[
1320,
63,
759
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
]
] | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound)
Gefitinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Primidone (Compound)
Gefitinib (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Primidone (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Primidone
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Primidone
Gefitinib (Compound) resembles Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Primidone |
DB00434 | DB00708 | 13 | 1,454 | [
"DDInter459",
"DDInter1718"
] | Cyproheptadine | Sufentanil | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments . Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately . The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 . This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration , . | Moderate | 1 | [
[
[
13,
24,
1454
]
],
[
[
13,
24,
704
],
[
704,
40,
1454
]
],
[
[
13,
21,
28658
],
[
28658,
60,
1454
]
],
[
[
13,
24,
537
],
[
537,
63,
1454
]
],
[
[
13,
24,
85
],
[
85,
24,
1454
]
],
[
[
13,
63,
352
],
[
352,
24,
1454
]
],
[
[
13,
24,
1039
],
[
1039,
64,
1454
]
],
[
[
13,
24,
121
],
[
121,
25,
1454
]
],
[
[
13,
24,
704
],
[
704,
1,
11366
],
[
11366,
40,
1454
]
],
[
[
13,
24,
1322
],
[
1322,
40,
704
],
[
704,
40,
1454
]
]
] | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Anileridine"
],
[
"Anileridine",
"{u} (Compound) resembles {v} (Compound)",
"Sufentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Sufentanil"
]
]
] | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Sufentanil (Compound)
Cyproheptadine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Sufentanil (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Sufentanil
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Sufentanil
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Anileridine (Compound) and Anileridine (Compound) resembles Sufentanil (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Sufentanil (Compound) |
DB08875 | DB11979 | 1,618 | 1,320 | [
"DDInter262",
"DDInter625"
] | Cabozantinib | Elagolix | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
1618,
24,
1320
]
],
[
[
1618,
25,
1612
],
[
1612,
23,
1320
]
],
[
[
1618,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
1618,
24,
1427
],
[
1427,
24,
1320
]
],
[
[
1618,
64,
79
],
[
79,
24,
1320
]
],
[
[
1618,
63,
1249
],
[
1249,
24,
1320
]
],
[
[
1618,
25,
877
],
[
877,
63,
1320
]
],
[
[
1618,
24,
159
],
[
159,
63,
1320
]
],
[
[
1618,
23,
1135
],
[
1135,
24,
1320
]
],
[
[
1618,
64,
463
],
[
463,
25,
1320
]
]
] | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
]
] | Cabozantinib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Cabozantinib may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cabozantinib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may lead to a major life threatening interaction when taken with Elagolix |
DB00486 | DB00794 | 1,614 | 759 | [
"DDInter1253",
"DDInter1521"
] | Nabilone | Primidone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
1614,
24,
759
]
],
[
[
1614,
24,
697
],
[
697,
40,
759
]
],
[
[
1614,
63,
362
],
[
362,
1,
759
]
],
[
[
1614,
24,
157
],
[
157,
1,
759
]
],
[
[
1614,
21,
28730
],
[
28730,
60,
759
]
],
[
[
1614,
24,
401
],
[
401,
63,
759
]
],
[
[
1614,
24,
832
],
[
832,
24,
759
]
],
[
[
1614,
63,
1242
],
[
1242,
24,
759
]
],
[
[
1614,
40,
530
],
[
530,
24,
759
]
],
[
[
1614,
63,
475
],
[
475,
25,
759
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
],
[
"Ethotoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Psychotic disorder"
],
[
"Psychotic disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
]
]
] | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Primidone (Compound)
Nabilone (Compound) causes Psychotic disorder (Side Effect) and Psychotic disorder (Side Effect) is caused by Primidone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Primidone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Primidone |
DB01224 | DB04843 | 623 | 1,511 | [
"DDInter1553",
"DDInter1149"
] | Quetiapine | Mepenzolate | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. | Moderate | 1 | [
[
[
623,
24,
1511
]
],
[
[
623,
63,
537
],
[
537,
24,
1511
]
],
[
[
623,
24,
649
],
[
649,
1,
1511
]
],
[
[
623,
24,
1429
],
[
1429,
63,
1511
]
],
[
[
623,
6,
7992
],
[
7992,
45,
1511
]
],
[
[
623,
7,
8953
],
[
8953,
46,
1511
]
],
[
[
623,
18,
5833
],
[
5833,
57,
1511
]
],
[
[
623,
21,
28975
],
[
28975,
60,
1511
]
],
[
[
623,
64,
475
],
[
475,
24,
1511
]
],
[
[
623,
74,
104
],
[
104,
24,
1511
]
]
] | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} (Compound) upregulates {v} (Gene)",
"NNT"
],
[
"NNT",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
]
] | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Mepenzolate (Compound)
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Quetiapine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Mepenzolate (Compound)
Quetiapine (Compound) upregulates NNT (Gene) and NNT (Gene) is upregulated by Mepenzolate (Compound)
Quetiapine (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Mepenzolate (Compound)
Quetiapine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Mepenzolate (Compound)
Quetiapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Quetiapine (Compound) resembles Methdilazine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate |
DB06663 | DB11757 | 1,154 | 960 | [
"DDInter1398",
"DDInter994"
] | Pasireotide | Istradefylline | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019. | Moderate | 1 | [
[
[
1154,
24,
960
]
],
[
[
1154,
64,
77
],
[
77,
24,
960
]
],
[
[
1154,
1,
966
],
[
966,
24,
960
]
],
[
[
1154,
25,
971
],
[
971,
63,
960
]
],
[
[
1154,
24,
850
],
[
850,
24,
960
]
],
[
[
1154,
24,
1017
],
[
1017,
63,
960
]
],
[
[
1154,
63,
543
],
[
543,
24,
960
]
],
[
[
1154,
25,
351
],
[
351,
24,
960
]
],
[
[
1154,
25,
913
],
[
913,
64,
960
]
],
[
[
1154,
24,
384
],
[
384,
25,
960
]
]
] | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} (Compound) resembles {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
]
] | Pasireotide may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Pasireotide may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Istradefylline
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Istradefylline |
DB00035 | DB00193 | 1,314 | 534 | [
"DDInter507",
"DDInter1841"
] | Desmopressin | Tramadol | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972 | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [duloxetine] and [venlafaxine]. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.[A183728,A183734,A183761,A17159,A182300] Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death.[A183830,F4679] However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.[A183836,A179926] | Moderate | 1 | [
[
[
1314,
24,
534
]
],
[
[
1314,
24,
1100
],
[
1100,
40,
534
]
],
[
[
1314,
21,
28987
],
[
28987,
60,
534
]
],
[
[
1314,
24,
1148
],
[
1148,
63,
534
]
],
[
[
1314,
24,
1264
],
[
1264,
64,
534
]
],
[
[
1314,
40,
1154
],
[
1154,
64,
534
]
],
[
[
1314,
24,
1100
],
[
1100,
25,
506
],
[
506,
1,
534
]
],
[
[
1314,
21,
28987
],
[
28987,
60,
1100
],
[
1100,
40,
534
]
],
[
[
1314,
21,
29173
],
[
29173,
60,
770
],
[
770,
63,
534
]
],
[
[
1314,
21,
28883
],
[
28883,
60,
112
],
[
112,
62,
534
]
]
] | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v} (Compound)",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tramadol"
]
]
] | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound)
Desmopressin (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Tramadol (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tramadol
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Tramadol
Desmopressin (Compound) resembles Pasireotide (Compound) and Pasireotide may lead to a major life threatening interaction when taken with Tramadol
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan (Compound) resembles Tramadol (Compound)
Desmopressin (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Venlafaxine (Compound) and Venlafaxine (Compound) resembles Tramadol (Compound)
Desmopressin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tramadol
Desmopressin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tramadol |
DB06663 | DB08868 | 1,154 | 1,011 | [
"DDInter1398",
"DDInter737"
] | Pasireotide | Fingolimod | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
1154,
25,
1011
]
],
[
[
1154,
21,
29203
],
[
29203,
60,
1011
]
],
[
[
1154,
62,
1247
],
[
1247,
23,
1011
]
],
[
[
1154,
24,
144
],
[
144,
63,
1011
]
],
[
[
1154,
63,
867
],
[
867,
24,
1011
]
],
[
[
1154,
64,
1052
],
[
1052,
24,
1011
]
],
[
[
1154,
25,
880
],
[
880,
63,
1011
]
],
[
[
1154,
64,
876
],
[
876,
25,
1011
]
],
[
[
1154,
63,
1592
],
[
1592,
25,
1011
]
],
[
[
1154,
25,
129
],
[
129,
64,
1011
]
]
] | [
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Pasireotide (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Fingolimod (Compound)
Pasireotide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pasireotide may lead to a major life threatening interaction when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pasireotide may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Pasireotide may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Fingolimod
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may lead to a major life threatening interaction when taken with Fingolimod
Pasireotide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fingolimod |
DB00861 | DB06603 | 914 | 39 | [
"DDInter551",
"DDInter1387"
] | Diflunisal | Panobinostat | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
914,
25,
39
]
],
[
[
914,
24,
578
],
[
578,
63,
39
]
],
[
[
914,
63,
1560
],
[
1560,
24,
39
]
],
[
[
914,
25,
4
],
[
4,
24,
39
]
],
[
[
914,
24,
1220
],
[
1220,
24,
39
]
],
[
[
914,
64,
663
],
[
663,
24,
39
]
],
[
[
914,
24,
976
],
[
976,
64,
39
]
],
[
[
914,
25,
1409
],
[
1409,
64,
39
]
],
[
[
914,
25,
500
],
[
500,
25,
39
]
],
[
[
914,
64,
553
],
[
553,
25,
39
]
]
] | [
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Diflunisal may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Diflunisal may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Panobinostat
Diflunisal may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Panobinostat
Diflunisal may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Panobinostat
Diflunisal may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Panobinostat |
DB00938 | DB15093 | 455 | 1,654 | [
"DDInter1635",
"DDInter1698"
] | Salmeterol | Somapacitan | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
455,
24,
1654
]
],
[
[
455,
24,
433
],
[
433,
24,
1654
]
],
[
[
455,
63,
176
],
[
176,
24,
1654
]
],
[
[
455,
25,
351
],
[
351,
24,
1654
]
],
[
[
455,
62,
167
],
[
167,
24,
1654
]
],
[
[
455,
23,
1486
],
[
1486,
24,
1654
]
],
[
[
455,
24,
433
],
[
433,
63,
168
],
[
168,
23,
1654
]
],
[
[
455,
63,
176
],
[
176,
24,
168
],
[
168,
23,
1654
]
],
[
[
455,
25,
351
],
[
351,
63,
10
],
[
10,
24,
1654
]
],
[
[
455,
63,
1010
],
[
1010,
63,
608
],
[
608,
23,
1654
]
]
] | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
]
] | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Salmeterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00563 | DB01177 | 663 | 77 | [
"DDInter1174",
"DDInter904"
] | Methotrexate | Idarubicin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
663,
24,
77
]
],
[
[
663,
5,
11579
],
[
11579,
44,
77
]
],
[
[
663,
6,
10417
],
[
10417,
45,
77
]
],
[
[
663,
7,
2903
],
[
2903,
46,
77
]
],
[
[
663,
18,
8527
],
[
8527,
57,
77
]
],
[
[
663,
7,
2309
],
[
2309,
57,
77
]
],
[
[
663,
21,
28931
],
[
28931,
60,
77
]
],
[
[
663,
24,
646
],
[
646,
23,
77
]
],
[
[
663,
63,
1467
],
[
1467,
23,
77
]
],
[
[
663,
24,
255
],
[
255,
62,
77
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"UBE2S"
],
[
"UBE2S",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"BRCA1"
],
[
"BRCA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
],
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
]
] | Methotrexate (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Idarubicin (Compound)
Methotrexate (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Idarubicin (Compound)
Methotrexate (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Idarubicin (Compound)
Methotrexate (Compound) downregulates UBE2S (Gene) and UBE2S (Gene) is downregulated by Idarubicin (Compound)
Methotrexate (Compound) upregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Idarubicin (Compound)
Methotrexate (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin |
DB00014 | DB00557 | 521 | 252 | [
"DDInter839",
"DDInter895"
] | Goserelin | Hydroxyzine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Moderate | 1 | [
[
[
521,
24,
252
]
],
[
[
521,
24,
1630
],
[
1630,
1,
252
]
],
[
[
521,
24,
623
],
[
623,
40,
252
]
],
[
[
521,
21,
28705
],
[
28705,
60,
252
]
],
[
[
521,
23,
112
],
[
112,
62,
252
]
],
[
[
521,
24,
1181
],
[
1181,
24,
252
]
],
[
[
521,
24,
820
],
[
820,
63,
252
]
],
[
[
521,
1,
774
],
[
774,
63,
252
]
],
[
[
521,
25,
877
],
[
877,
64,
252
]
],
[
[
521,
25,
702
],
[
702,
25,
252
]
]
] | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Drowsiness"
],
[
"Drowsiness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
]
] | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Goserelin (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Hydroxyzine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Hydroxyzine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Goserelin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Hydroxyzine
Goserelin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Hydroxyzine |
DB00620 | DB11110 | 175 | 603 | [
"DDInter1855",
"DDInter1115"
] | Triamcinolone | Magnesium citrate | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
175,
24,
603
]
],
[
[
175,
63,
789
],
[
789,
24,
603
]
],
[
[
175,
25,
246
],
[
246,
24,
603
]
],
[
[
175,
40,
870
],
[
870,
24,
603
]
],
[
[
175,
24,
1326
],
[
1326,
24,
603
]
],
[
[
175,
64,
1176
],
[
1176,
24,
603
]
],
[
[
175,
23,
688
],
[
688,
24,
603
]
],
[
[
175,
24,
1375
],
[
1375,
63,
603
]
],
[
[
175,
25,
255
],
[
255,
63,
603
]
],
[
[
175,
63,
789
],
[
789,
25,
57
],
[
57,
24,
603
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB01110 | DB15091 | 86 | 676 | [
"DDInter1209",
"DDInter1901"
] | Miconazole | Upadacitinib | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Moderate | 1 | [
[
[
86,
24,
676
]
],
[
[
86,
24,
1593
],
[
1593,
24,
676
]
],
[
[
86,
63,
600
],
[
600,
24,
676
]
],
[
[
86,
62,
690
],
[
690,
24,
676
]
],
[
[
86,
24,
503
],
[
503,
25,
676
]
],
[
[
86,
63,
629
],
[
629,
25,
676
]
],
[
[
86,
62,
1091
],
[
1091,
25,
676
]
],
[
[
86,
24,
1650
],
[
1650,
64,
676
]
],
[
[
86,
24,
1593
],
[
1593,
63,
1249
],
[
1249,
24,
676
]
],
[
[
86,
24,
655
],
[
655,
25,
283
],
[
283,
24,
676
]
]
] | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
]
] | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Miconazole may cause a minor interaction that can limit clinical effects when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib
Miconazole may cause a minor interaction that can limit clinical effects when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib |
DB00175 | DB09570 | 681 | 1,480 | [
"DDInter1509",
"DDInter1002"
] | Pravastatin | Ixazomib | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
681,
24,
1480
]
],
[
[
681,
63,
268
],
[
268,
24,
1480
]
],
[
[
681,
24,
148
],
[
148,
63,
1480
]
],
[
[
681,
24,
310
],
[
310,
24,
1480
]
],
[
[
681,
1,
1463
],
[
1463,
24,
1480
]
],
[
[
681,
35,
467
],
[
467,
24,
1480
]
],
[
[
681,
24,
375
],
[
375,
25,
1480
]
],
[
[
681,
25,
1377
],
[
1377,
25,
1480
]
],
[
[
681,
63,
1057
],
[
1057,
25,
1480
]
],
[
[
681,
24,
913
],
[
913,
64,
1480
]
]
] | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound)",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
]
] | Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pravastatin (Compound) resembles Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pravastatin (Compound) resembles Simvastatin (Compound) and Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib
Pravastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ixazomib
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixazomib
Pravastatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ixazomib |
DB01235 | DB08904 | 1,191 | 375 | [
"DDInter1054",
"DDInter342"
] | Levodopa | Certolizumab pegol | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Moderate | 1 | [
[
[
1191,
24,
375
]
],
[
[
1191,
24,
1047
],
[
1047,
24,
375
]
],
[
[
1191,
24,
1434
],
[
1434,
63,
375
]
],
[
[
1191,
63,
10
],
[
10,
24,
375
]
],
[
[
1191,
63,
63
],
[
63,
25,
375
]
],
[
[
1191,
24,
1480
],
[
1480,
64,
375
]
],
[
[
1191,
24,
1626
],
[
1626,
25,
375
]
],
[
[
1191,
1,
1307
],
[
1307,
25,
375
]
],
[
[
1191,
64,
1053
],
[
1053,
25,
375
]
],
[
[
1191,
24,
1047
],
[
1047,
63,
231
],
[
231,
24,
375
]
]
] | [
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
],
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Melphalan"
],
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
]
] | Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab and Elotuzumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Levodopa (Compound) resembles Melphalan (Compound) and Melphalan may lead to a major life threatening interaction when taken with Certolizumab pegol
Levodopa may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Certolizumab pegol
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol |
DB01404 | DB09564 | 757 | 1,296 | [
"DDInter820",
"DDInter930"
] | Ginseng | Insulin degludec | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
757,
24,
1296
]
],
[
[
757,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
757,
24,
761
],
[
761,
24,
1296
]
],
[
[
757,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
757,
63,
1411
],
[
1411,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
757,
24,
761
],
[
761,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
757,
63,
1479
],
[
1479,
62,
17
],
[
17,
24,
1296
]
],
[
[
757,
24,
1450
],
[
1450,
63,
274
],
[
274,
23,
1296
]
],
[
[
757,
63,
1324
],
[
1324,
23,
1103
],
[
1103,
23,
1296
]
],
[
[
757,
63,
25
],
[
25,
23,
1631
],
[
1631,
63,
1296
]
]
] | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
]
] | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec |
DB00321 | DB00526 | 21 | 1,555 | [
"DDInter78",
"DDInter1355"
] | Amitriptyline | Oxaliplatin | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®. | Moderate | 1 | [
[
[
21,
24,
1555
]
],
[
[
21,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
21,
24,
79
],
[
79,
24,
1555
]
],
[
[
21,
24,
1213
],
[
1213,
63,
1555
]
],
[
[
21,
63,
618
],
[
618,
24,
1555
]
],
[
[
21,
1,
508
],
[
508,
24,
1555
]
],
[
[
21,
35,
820
],
[
820,
63,
1555
]
],
[
[
21,
25,
1133
],
[
1133,
63,
1555
]
],
[
[
21,
25,
1494
],
[
1494,
24,
1555
]
],
[
[
21,
1,
1237
],
[
1237,
63,
1555
]
]
] | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
]
] | Amitriptyline (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline (Compound) resembles Alimemazine (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Amitriptyline (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin |
DB00384 | DB00501 | 1,275 | 752 | [
"DDInter1859",
"DDInter380"
] | Triamterene | Cimetidine | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Minor | 0 | [
[
[
1275,
23,
752
]
],
[
[
1275,
6,
7950
],
[
7950,
45,
752
]
],
[
[
1275,
21,
28784
],
[
28784,
60,
752
]
],
[
[
1275,
24,
286
],
[
286,
62,
752
]
],
[
[
1275,
24,
613
],
[
613,
63,
752
]
],
[
[
1275,
63,
475
],
[
475,
24,
752
]
],
[
[
1275,
6,
7950
],
[
7950,
45,
510
],
[
510,
62,
752
]
],
[
[
1275,
21,
28784
],
[
28784,
60,
935
],
[
935,
62,
752
]
],
[
[
1275,
24,
286
],
[
286,
62,
831
],
[
831,
23,
752
]
],
[
[
1275,
24,
1512
],
[
1512,
6,
4973
],
[
4973,
45,
752
]
]
] | [
[
[
"Triamterene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Albendazole"
],
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
]
] | Triamterene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cimetidine (Compound)
Triamterene (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Cimetidine (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Triamterene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Albendazole (Compound) and Albendazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Triamterene (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ketoprofen (Compound) and Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound) |
DB06605 | DB08873 | 1,409 | 74 | [
"DDInter108",
"DDInter221"
] | Apixaban | Boceprevir | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Major | 2 | [
[
[
1409,
25,
74
]
],
[
[
1409,
6,
4973
],
[
4973,
45,
74
]
],
[
[
1409,
21,
28789
],
[
28789,
60,
74
]
],
[
[
1409,
63,
1374
],
[
1374,
23,
74
]
],
[
[
1409,
24,
1496
],
[
1496,
63,
74
]
],
[
[
1409,
63,
1424
],
[
1424,
24,
74
]
],
[
[
1409,
64,
126
],
[
126,
24,
74
]
],
[
[
1409,
25,
1421
],
[
1421,
63,
74
]
],
[
[
1409,
24,
124
],
[
124,
64,
74
]
],
[
[
1409,
25,
129
],
[
129,
64,
74
]
]
] | [
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
]
] | Apixaban (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Apixaban (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Boceprevir (Compound)
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Apixaban may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Apixaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Boceprevir
Apixaban may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Boceprevir |
DB00404 | DB12500 | 523 | 283 | [
"DDInter54",
"DDInter714"
] | Alprazolam | Fedratinib | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
523,
24,
283
]
],
[
[
523,
24,
351
],
[
351,
23,
283
]
],
[
[
523,
24,
1419
],
[
1419,
24,
283
]
],
[
[
523,
1,
481
],
[
481,
24,
283
]
],
[
[
523,
64,
600
],
[
600,
24,
283
]
],
[
[
523,
23,
891
],
[
891,
24,
283
]
],
[
[
523,
40,
1382
],
[
1382,
24,
283
]
],
[
[
523,
63,
1101
],
[
1101,
24,
283
]
],
[
[
523,
24,
159
],
[
159,
63,
283
]
],
[
[
523,
24,
1017
],
[
1017,
25,
283
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib |
DB00022 | DB14730 | 268 | 1,412 | [
"DDInter1408",
"DDInter264"
] | Peginterferon alfa-2b | Calaspargase pegol | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
268,
24,
1412
]
],
[
[
268,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
268,
63,
491
],
[
491,
24,
1412
]
],
[
[
268,
25,
593
],
[
593,
24,
1412
]
],
[
[
268,
24,
770
],
[
770,
25,
1412
]
],
[
[
268,
25,
1101
],
[
1101,
25,
1412
]
],
[
[
268,
24,
1439
],
[
1439,
25,
792
],
[
792,
24,
1412
]
],
[
[
268,
24,
322
],
[
322,
24,
250
],
[
250,
24,
1412
]
],
[
[
268,
63,
491
],
[
491,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
268,
25,
593
],
[
593,
25,
250
],
[
250,
24,
1412
]
]
] | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB08820 | DB11986 | 1,478 | 484 | [
"DDInter997",
"DDInter648"
] | Ivacaftor | Entrectinib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
1478,
24,
484
]
],
[
[
1478,
63,
1247
],
[
1247,
23,
484
]
],
[
[
1478,
23,
271
],
[
271,
23,
484
]
],
[
[
1478,
23,
907
],
[
907,
62,
484
]
],
[
[
1478,
63,
510
],
[
510,
24,
484
]
],
[
[
1478,
24,
1320
],
[
1320,
24,
484
]
],
[
[
1478,
24,
242
],
[
242,
63,
484
]
],
[
[
1478,
64,
1554
],
[
1554,
24,
484
]
],
[
[
1478,
25,
1456
],
[
1456,
24,
484
]
],
[
[
1478,
62,
479
],
[
479,
24,
484
]
]
] | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albendazole"
],
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
]
] | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ivacaftor may lead to a major life threatening interaction when taken with Colchicine and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ivacaftor may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib |
DB00679 | DB06335 | 684 | 761 | [
"DDInter1796",
"DDInter1646"
] | Thioridazine | Saxagliptin | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
684,
24,
761
]
],
[
[
684,
21,
28722
],
[
28722,
60,
761
]
],
[
[
684,
25,
1491
],
[
1491,
63,
761
]
],
[
[
684,
36,
104
],
[
104,
24,
761
]
],
[
[
684,
24,
1296
],
[
1296,
63,
761
]
],
[
[
684,
40,
1630
],
[
1630,
24,
761
]
],
[
[
684,
24,
1042
],
[
1042,
24,
761
]
],
[
[
684,
25,
478
],
[
478,
24,
761
]
],
[
[
684,
64,
600
],
[
600,
24,
761
]
],
[
[
684,
63,
1179
],
[
1179,
24,
761
]
]
] | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
]
] | Thioridazine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Thioridazine may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine (Compound) resembles Methdilazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin |
DB01362 | DB05260 | 497 | 1,329 | [
"DDInter960",
"DDInter804"
] | Iohexol | Gallium nitrate | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Gallium nitrate is a nitrate salt of , a heavy metal that has been used as a diagnostic agent. Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness. Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours. | Major | 2 | [
[
[
497,
25,
1329
]
],
[
[
497,
21,
28746
],
[
28746,
60,
1329
]
],
[
[
497,
64,
712
],
[
712,
24,
1329
]
],
[
[
497,
64,
361
],
[
361,
25,
1329
]
],
[
[
497,
1,
258
],
[
258,
25,
1329
]
],
[
[
497,
21,
28746
],
[
28746,
60,
372
],
[
372,
24,
1329
]
],
[
[
497,
64,
712
],
[
712,
63,
1555
],
[
1555,
24,
1329
]
],
[
[
497,
64,
372
],
[
372,
6,
6896
],
[
6896,
45,
1329
]
],
[
[
497,
64,
361
],
[
361,
21,
28746
],
[
28746,
60,
1329
]
],
[
[
497,
64,
684
],
[
684,
18,
6896
],
[
6896,
45,
1329
]
]
] | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} (Compound) resembles {v} (Compound)",
"Iodixanol"
],
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} (Compound) binds {v} (Gene)",
"RRM2"
],
[
"RRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gallium nitrate"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"RRM2"
],
[
"RRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Gallium nitrate"
]
]
] | Iohexol (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Gallium nitrate (Compound)
Iohexol may lead to a major life threatening interaction when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Iohexol may lead to a major life threatening interaction when taken with Neomycin and Neomycin may lead to a major life threatening interaction when taken with Gallium nitrate
Iohexol (Compound) resembles Iodixanol (Compound) and Iodixanol may lead to a major life threatening interaction when taken with Gallium nitrate
Iohexol (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Iohexol may lead to a major life threatening interaction when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gallium nitrate
Iohexol may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) binds RRM2 (Gene) and RRM2 (Gene) is bound by Gallium nitrate (Compound)
Iohexol may lead to a major life threatening interaction when taken with Neomycin and Neomycin (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Gallium nitrate (Compound)
Iohexol may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is bound by Gallium nitrate (Compound) |
DB06288 | DB11730 | 607 | 351 | [
"DDInter77",
"DDInter1588"
] | Amisulpride | Ribociclib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
607,
25,
351
]
],
[
[
607,
62,
112
],
[
112,
23,
351
]
],
[
[
607,
63,
355
],
[
355,
24,
351
]
],
[
[
607,
25,
1491
],
[
1491,
24,
351
]
],
[
[
607,
24,
657
],
[
657,
24,
351
]
],
[
[
607,
25,
129
],
[
129,
25,
351
]
],
[
[
607,
25,
1297
],
[
1297,
64,
351
]
],
[
[
607,
64,
77
],
[
77,
25,
351
]
],
[
[
607,
24,
1019
],
[
1019,
64,
351
]
],
[
[
607,
24,
144
],
[
144,
25,
351
]
]
] | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Ribociclib
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may lead to a major life threatening interaction when taken with Ribociclib |
DB01100 | DB14723 | 1,568 | 159 | [
"DDInter1470",
"DDInter1026"
] | Pimozide | Larotrectinib | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Major | 2 | [
[
[
1568,
25,
159
]
],
[
[
1568,
24,
222
],
[
222,
23,
159
]
],
[
[
1568,
25,
741
],
[
741,
24,
159
]
],
[
[
1568,
1,
78
],
[
78,
24,
159
]
],
[
[
1568,
24,
98
],
[
98,
24,
159
]
],
[
[
1568,
64,
597
],
[
597,
24,
159
]
],
[
[
1568,
63,
912
],
[
912,
24,
159
]
],
[
[
1568,
25,
129
],
[
129,
25,
159
]
],
[
[
1568,
24,
222
],
[
222,
25,
318
],
[
318,
23,
159
]
],
[
[
1568,
25,
741
],
[
741,
62,
479
],
[
479,
23,
159
]
]
] | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} (Compound) resembles {v} (Compound)",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
]
] | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pimozide may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pimozide (Compound) resembles Droperidol (Compound) and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pimozide may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pimozide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pimozide may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB00631 | DB14409 | 372 | 1,129 | [
"DDInter405",
"DDInter867"
] | Clofarabine | Human adenovirus e serotype 4 strain cl-68578 antigen | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
372,
24,
1129
]
],
[
[
372,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
372,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
372,
63,
134
],
[
134,
24,
1129
]
],
[
[
372,
25,
1259
],
[
1259,
24,
1129
]
],
[
[
372,
25,
676
],
[
676,
63,
1129
]
],
[
[
372,
1,
1488
],
[
1488,
24,
1129
]
],
[
[
372,
35,
1224
],
[
1224,
24,
1129
]
],
[
[
372,
64,
1057
],
[
1057,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
372,
24,
1683
],
[
1683,
64,
1057
],
[
1057,
24,
1129
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
]
] | Clofarabine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine (Compound) resembles Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine (Compound) resembles Cytarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB01227 | DB14568 | 1,301 | 982 | [
"DDInter1043",
"DDInter1000"
] | Levacetylmethadol | Ivosidenib | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862] | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
1301,
25,
982
]
],
[
[
1301,
62,
112
],
[
112,
23,
982
]
],
[
[
1301,
64,
1101
],
[
1101,
23,
982
]
],
[
[
1301,
24,
976
],
[
976,
24,
982
]
],
[
[
1301,
74,
543
],
[
543,
24,
982
]
],
[
[
1301,
63,
770
],
[
770,
24,
982
]
],
[
[
1301,
25,
1383
],
[
1383,
24,
982
]
],
[
[
1301,
25,
159
],
[
159,
63,
982
]
],
[
[
1301,
40,
307
],
[
307,
24,
982
]
],
[
[
1301,
64,
11
],
[
11,
25,
982
]
]
] | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
]
] | Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Levacetylmethadol may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol (Compound) resembles Loperamide (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levacetylmethadol may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib |
DB01073 | DB04865 | 1,488 | 4 | [
"DDInter745",
"DDInter1335"
] | Fludarabine | Omacetaxine mepesuccinate | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
1488,
24,
4
]
],
[
[
1488,
64,
770
],
[
770,
24,
4
]
],
[
[
1488,
24,
496
],
[
496,
63,
4
]
],
[
[
1488,
63,
66
],
[
66,
24,
4
]
],
[
[
1488,
24,
1532
],
[
1532,
24,
4
]
],
[
[
1488,
40,
1426
],
[
1426,
24,
4
]
],
[
[
1488,
74,
1224
],
[
1224,
24,
4
]
],
[
[
1488,
63,
1317
],
[
1317,
25,
4
]
],
[
[
1488,
25,
1292
],
[
1292,
64,
4
]
],
[
[
1488,
64,
1066
],
[
1066,
25,
4
]
]
] | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound)",
"Azacitidine"
],
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Fludarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine (Compound) resembles Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine (Compound) resembles Cytarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Fludarabine may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Fludarabine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate |
DB00701 | DB06595 | 1,091 | 1,491 | [
"DDInter90",
"DDInter1214"
] | Amprenavir | Midostaurin | Amprenavir is a protease inhibitor used to treat HIV infection. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
1091,
24,
1491
]
],
[
[
1091,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
1091,
25,
112
],
[
112,
23,
1491
]
],
[
[
1091,
24,
761
],
[
761,
24,
1491
]
],
[
[
1091,
24,
1017
],
[
1017,
63,
1491
]
],
[
[
1091,
63,
1647
],
[
1647,
24,
1491
]
],
[
[
1091,
25,
927
],
[
927,
63,
1491
]
],
[
[
1091,
64,
134
],
[
134,
24,
1491
]
],
[
[
1091,
25,
613
],
[
613,
24,
1491
]
],
[
[
1091,
23,
86
],
[
86,
24,
1491
]
]
] | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
]
] | Amprenavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Amprenavir may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin |
DB00888 | DB01097 | 1,001 | 1,377 | [
"DDInter1133",
"DDInter1033"
] | Mechlorethamine | Leflunomide | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1001,
25,
1377
]
],
[
[
1001,
21,
28864
],
[
28864,
60,
1377
]
],
[
[
1001,
63,
1461
],
[
1461,
23,
1377
]
],
[
[
1001,
24,
949
],
[
949,
63,
1377
]
],
[
[
1001,
62,
126
],
[
126,
24,
1377
]
],
[
[
1001,
24,
563
],
[
563,
24,
1377
]
],
[
[
1001,
63,
597
],
[
597,
24,
1377
]
],
[
[
1001,
63,
66
],
[
66,
25,
1377
]
],
[
[
1001,
25,
779
],
[
779,
64,
1377
]
],
[
[
1001,
24,
1307
],
[
1307,
25,
1377
]
]
] | [
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema multiforme"
],
[
"Erythema multiforme",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Mechlorethamine (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Leflunomide (Compound)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may lead to a major life threatening interaction when taken with Leflunomide
Mechlorethamine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Leflunomide
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may lead to a major life threatening interaction when taken with Leflunomide |
DB01155 | DB13928 | 872 | 1,385 | [
"DDInter813",
"DDInter1660"
] | Gemifloxacin | Semaglutide | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective. | Moderate | 1 | [
[
[
872,
24,
1385
]
],
[
[
872,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
872,
64,
891
],
[
891,
24,
1385
]
],
[
[
872,
63,
1148
],
[
1148,
24,
1385
]
],
[
[
872,
40,
739
],
[
739,
24,
1385
]
],
[
[
872,
1,
945
],
[
945,
24,
1385
]
],
[
[
872,
24,
659
],
[
659,
24,
1385
]
],
[
[
872,
40,
246
],
[
246,
25,
1385
]
],
[
[
872,
25,
1154
],
[
1154,
25,
1399
],
[
1399,
63,
1385
]
],
[
[
872,
64,
891
],
[
891,
40,
1103
],
[
1103,
23,
1385
]
]
] | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Semaglutide"
]
]
] | Gemifloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Semaglutide
Gemifloxacin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Gemifloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide |
DB00928 | DB04865 | 1,426 | 4 | [
"DDInter148",
"DDInter1335"
] | Azacitidine | Omacetaxine mepesuccinate | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and inhibiting protein and DNA synthesis. The other one is through the inhibition of DNA methyltransferase, impairing DNA methylation. Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA, azacytidine has been used mainly used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation.[ | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
1426,
24,
4
]
],
[
[
1426,
7,
4811
],
[
4811,
46,
4
]
],
[
[
1426,
18,
3151
],
[
3151,
46,
4
]
],
[
[
1426,
18,
10488
],
[
10488,
57,
4
]
],
[
[
1426,
7,
13388
],
[
13388,
57,
4
]
],
[
[
1426,
25,
770
],
[
770,
24,
4
]
],
[
[
1426,
24,
496
],
[
496,
63,
4
]
],
[
[
1426,
63,
66
],
[
66,
24,
4
]
],
[
[
1426,
1,
1488
],
[
1488,
24,
4
]
],
[
[
1426,
24,
563
],
[
563,
24,
4
]
]
] | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} (Compound) upregulates {v} (Gene)",
"DUSP6"
],
[
"DUSP6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} (Compound) downregulates {v} (Gene)",
"DDB2"
],
[
"DDB2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} (Compound) downregulates {v} (Gene)",
"B4GAT1"
],
[
"B4GAT1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} (Compound) upregulates {v} (Gene)",
"PSAT1"
],
[
"PSAT1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Azacitidine (Compound) upregulates DUSP6 (Gene) and DUSP6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Azacitidine (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Azacitidine (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Azacitidine (Compound) upregulates PSAT1 (Gene) and PSAT1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Azacitidine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Azacitidine (Compound) resembles Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB00912 | DB00976 | 473 | 1,056 | [
"DDInter1581",
"DDInter1758"
] | Repaglinide | Telithromycin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Moderate | 1 | [
[
[
473,
24,
1056
]
],
[
[
473,
6,
8374
],
[
8374,
45,
1056
]
],
[
[
473,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
473,
24,
1220
],
[
1220,
63,
1056
]
],
[
[
473,
63,
1051
],
[
1051,
24,
1056
]
],
[
[
473,
24,
1510
],
[
1510,
64,
1056
]
],
[
[
473,
63,
629
],
[
629,
25,
1056
]
],
[
[
473,
24,
455
],
[
455,
25,
1056
]
],
[
[
473,
24,
609
],
[
609,
74,
1056
]
],
[
[
473,
6,
8374
],
[
8374,
45,
1570
],
[
1570,
40,
1056
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
]
]
] | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Repaglinide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Telithromycin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Telithromycin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Telithromycin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin (Compound) resembles Telithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Azithromycin (Compound) and Azithromycin (Compound) resembles Telithromycin (Compound) |
DB01263 | DB11901 | 859 | 913 | [
"DDInter1494",
"DDInter107"
] | Posaconazole | Apalutamide | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
859,
24,
913
]
],
[
[
859,
62,
112
],
[
112,
23,
913
]
],
[
[
859,
63,
608
],
[
608,
23,
913
]
],
[
[
859,
63,
600
],
[
600,
24,
913
]
],
[
[
859,
24,
28
],
[
28,
24,
913
]
],
[
[
859,
25,
1320
],
[
1320,
63,
913
]
],
[
[
859,
64,
467
],
[
467,
24,
913
]
],
[
[
859,
25,
1468
],
[
1468,
24,
913
]
],
[
[
859,
24,
1619
],
[
1619,
63,
913
]
],
[
[
859,
25,
564
],
[
564,
64,
913
]
]
] | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Posaconazole may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib may lead to a major life threatening interaction when taken with Apalutamide |
DB00035 | DB14881 | 1,314 | 180 | [
"DDInter507",
"DDInter1329"
] | Desmopressin | Oliceridine | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972 | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
1314,
24,
180
]
],
[
[
1314,
24,
407
],
[
407,
24,
180
]
],
[
[
1314,
40,
1154
],
[
1154,
25,
180
]
],
[
[
1314,
25,
1220
],
[
1220,
25,
180
]
],
[
[
1314,
24,
475
],
[
475,
25,
180
]
],
[
[
1314,
24,
407
],
[
407,
63,
401
],
[
401,
24,
180
]
],
[
[
1314,
24,
1264
],
[
1264,
62,
112
],
[
112,
23,
180
]
],
[
[
1314,
24,
1148
],
[
1148,
24,
401
],
[
401,
24,
180
]
],
[
[
1314,
24,
543
],
[
543,
24,
112
],
[
112,
23,
180
]
],
[
[
1314,
40,
1154
],
[
1154,
62,
112
],
[
112,
23,
180
]
]
] | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
]
] | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Desmopressin (Compound) resembles Pasireotide (Compound) and Pasireotide may lead to a major life threatening interaction when taken with Oliceridine
Desmopressin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Oliceridine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Oliceridine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Desmopressin (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine |
DB00352 | DB00621 | 482 | 1,026 | [
"DDInter1814",
"DDInter1357"
] | Tioguanine | Oxandrolone | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | A synthetic hormone with anabolic and androgenic properties. | Moderate | 1 | [
[
[
482,
24,
1026
]
],
[
[
482,
24,
1546
],
[
1546,
1,
1026
]
],
[
[
482,
21,
30839
],
[
30839,
60,
1026
]
],
[
[
482,
24,
671
],
[
671,
63,
1026
]
],
[
[
482,
63,
912
],
[
912,
24,
1026
]
],
[
[
482,
24,
322
],
[
322,
24,
1026
]
],
[
[
482,
25,
1510
],
[
1510,
64,
1026
]
],
[
[
482,
24,
350
],
[
350,
64,
1026
]
],
[
[
482,
24,
1546
],
[
1546,
40,
11326
],
[
11326,
1,
1026
]
],
[
[
482,
21,
30839
],
[
30839,
60,
1546
],
[
1546,
1,
1026
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Peliosis hepatis"
],
[
"Peliosis hepatis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Allylestrenol"
],
[
"Allylestrenol",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Peliosis hepatis"
],
[
"Peliosis hepatis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
]
] | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Oxandrolone (Compound)
Tioguanine (Compound) causes Peliosis hepatis (Side Effect) and Peliosis hepatis (Side Effect) is caused by Oxandrolone (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Tioguanine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Oxandrolone
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Oxandrolone
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Allylestrenol (Compound) and Allylestrenol (Compound) resembles Oxandrolone (Compound)
Tioguanine (Compound) causes Peliosis hepatis (Side Effect) and Peliosis hepatis (Side Effect) is caused by Methyltestosterone (Compound) and Methyltestosterone (Compound) resembles Oxandrolone (Compound) |
DB00352 | DB10795 | 482 | 221 | [
"DDInter1814",
"DDInter1486"
] | Tioguanine | Poliovirus type 1 antigen (formaldehyde inactivated) | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
482,
24,
221
]
],
[
[
482,
64,
581
],
[
581,
24,
221
]
],
[
[
482,
24,
350
],
[
350,
24,
221
]
],
[
[
482,
63,
599
],
[
599,
24,
221
]
],
[
[
482,
25,
1510
],
[
1510,
24,
221
]
],
[
[
482,
24,
351
],
[
351,
63,
221
]
],
[
[
482,
25,
676
],
[
676,
63,
221
]
],
[
[
482,
35,
328
],
[
328,
24,
221
]
],
[
[
482,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
],
[
[
482,
24,
350
],
[
350,
63,
36
],
[
36,
24,
221
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] | Tioguanine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB09104 | DB12147 | 286 | 241 | [
"DDInter1118",
"DDInter661"
] | Magnesium hydroxide | Erdafitinib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition. | Major | 2 | [
[
[
286,
25,
241
]
],
[
[
286,
24,
982
],
[
982,
63,
241
]
],
[
[
286,
63,
1425
],
[
1425,
24,
241
]
],
[
[
286,
63,
1220
],
[
1220,
25,
241
]
],
[
[
286,
24,
460
],
[
460,
25,
241
]
],
[
[
286,
24,
982
],
[
982,
63,
1456
],
[
1456,
24,
241
]
],
[
[
286,
63,
1425
],
[
1425,
25,
384
],
[
384,
24,
241
]
],
[
[
286,
63,
1413
],
[
1413,
24,
1456
],
[
1456,
24,
241
]
],
[
[
286,
63,
868
],
[
868,
63,
170
],
[
170,
24,
241
]
],
[
[
286,
63,
1196
],
[
1196,
24,
1619
],
[
1619,
63,
241
]
]
] | [
[
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
]
] | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may lead to a major life threatening interaction when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib |
DB06616 | DB10316 | 594 | 334 | [
"DDInter224",
"DDInter1248"
] | Bosutinib | Mumps virus strain B level jeryl lynn live antigen | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
594,
25,
334
]
],
[
[
594,
64,
1057
],
[
1057,
25,
334
]
],
[
[
594,
25,
908
],
[
908,
25,
334
]
],
[
[
594,
63,
1491
],
[
1491,
25,
334
]
],
[
[
594,
24,
1619
],
[
1619,
64,
334
]
],
[
[
594,
24,
850
],
[
850,
25,
334
]
],
[
[
594,
25,
1259
],
[
1259,
64,
334
]
],
[
[
594,
64,
1057
],
[
1057,
25,
1042
],
[
1042,
24,
334
]
],
[
[
594,
25,
908
],
[
908,
64,
1042
],
[
1042,
24,
334
]
],
[
[
594,
63,
1491
],
[
1491,
64,
1057
],
[
1057,
25,
334
]
]
] | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
]
] | Bosutinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen |
DB01254 | DB06772 | 1,213 | 310 | [
"DDInter484",
"DDInter259"
] | Dasatinib | Cabazitaxel | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
1213,
24,
310
]
],
[
[
1213,
63,
973
],
[
973,
24,
310
]
],
[
[
1213,
6,
7524
],
[
7524,
45,
310
]
],
[
[
1213,
18,
16974
],
[
16974,
45,
310
]
],
[
[
1213,
21,
28894
],
[
28894,
60,
310
]
],
[
[
1213,
63,
307
],
[
307,
23,
310
]
],
[
[
1213,
24,
800
],
[
800,
63,
310
]
],
[
[
1213,
25,
868
],
[
868,
63,
310
]
],
[
[
1213,
64,
798
],
[
798,
24,
310
]
],
[
[
1213,
24,
1430
],
[
1430,
24,
310
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} (Compound) downregulates {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure"
],
[
"Cardiac failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Dasatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Cabazitaxel (Compound)
Dasatinib (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is bound by Cabazitaxel (Compound)
Dasatinib (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Cabazitaxel (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Dasatinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Dasatinib may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB00515 | DB00563 | 589 | 663 | [
"DDInter387",
"DDInter1174"
] | Cisplatin | Methotrexate | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Moderate | 1 | [
[
[
589,
24,
663
]
],
[
[
589,
5,
11655
],
[
11655,
44,
663
]
],
[
[
589,
6,
4973
],
[
4973,
45,
663
]
],
[
[
589,
6,
7720
],
[
7720,
46,
663
]
],
[
[
589,
21,
28681
],
[
28681,
60,
663
]
],
[
[
589,
24,
328
],
[
328,
62,
663
]
],
[
[
589,
63,
1300
],
[
1300,
23,
663
]
],
[
[
589,
24,
1287
],
[
1287,
63,
663
]
],
[
[
589,
63,
91
],
[
91,
24,
663
]
],
[
[
589,
25,
33
],
[
33,
63,
663
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} (Compound) treats {v} (Disease)",
"bone cancer"
],
[
"bone cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
]
] | Cisplatin (Compound) treats bone cancer (Disease) and bone cancer (Disease) is treated by Methotrexate (Compound)
Cisplatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methotrexate (Compound)
Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Methotrexate (Compound)
Cisplatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Cisplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate |
DB00653 | DB01044 | 544 | 246 | [
"DDInter1120",
"DDInter809"
] | Magnesium sulfate | Gatifloxacin | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Moderate | 1 | [
[
[
544,
24,
246
]
],
[
[
544,
24,
739
],
[
739,
1,
246
]
],
[
[
544,
63,
1176
],
[
1176,
1,
246
]
],
[
[
544,
24,
945
],
[
945,
40,
246
]
],
[
[
544,
63,
1467
],
[
1467,
40,
246
]
],
[
[
544,
21,
29316
],
[
29316,
60,
246
]
],
[
[
544,
24,
613
],
[
613,
23,
246
]
],
[
[
544,
24,
603
],
[
603,
63,
246
]
],
[
[
544,
63,
355
],
[
355,
24,
246
]
],
[
[
544,
63,
251
],
[
251,
25,
246
]
]
] | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
]
] | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Gatifloxacin (Compound)
Magnesium sulfate (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Gatifloxacin (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Gatifloxacin |
DB04845 | DB09118 | 309 | 1,580 | [
"DDInter1001",
"DDInter1711"
] | Ixabepilone | Stiripentol | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
309,
24,
1580
]
],
[
[
309,
24,
283
],
[
283,
63,
1580
]
],
[
[
309,
63,
168
],
[
168,
24,
1580
]
],
[
[
309,
24,
98
],
[
98,
24,
1580
]
],
[
[
309,
25,
976
],
[
976,
24,
1580
]
],
[
[
309,
25,
676
],
[
676,
63,
1580
]
],
[
[
309,
25,
1292
],
[
1292,
25,
1580
]
],
[
[
309,
24,
982
],
[
982,
64,
1580
]
],
[
[
309,
24,
1362
],
[
1362,
25,
1580
]
],
[
[
309,
24,
283
],
[
283,
23,
466
],
[
466,
62,
1580
]
]
] | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Stiripentol"
]
]
] | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ixabepilone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ixabepilone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ixabepilone may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Stiripentol
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Stiripentol
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Stiripentol
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol |
DB09074 | DB11967 | 1,362 | 710 | [
"DDInter1327",
"DDInter210"
] | Olaparib | Binimetinib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
1362,
24,
710
]
],
[
[
1362,
64,
441
],
[
441,
24,
710
]
],
[
[
1362,
63,
371
],
[
371,
24,
710
]
],
[
[
1362,
25,
68
],
[
68,
63,
710
]
],
[
[
1362,
24,
733
],
[
733,
63,
710
]
],
[
[
1362,
25,
351
],
[
351,
24,
710
]
],
[
[
1362,
24,
985
],
[
985,
24,
710
]
],
[
[
1362,
24,
405
],
[
405,
25,
710
]
],
[
[
1362,
63,
770
],
[
770,
25,
710
]
],
[
[
1362,
64,
1510
],
[
1510,
25,
710
]
]
] | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
],
[
"Eslicarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
]
] | Olaparib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Binimetinib
Olaparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Binimetinib |
DB00404 | DB00651 | 523 | 746 | [
"DDInter54",
"DDInter613"
] | Alprazolam | Dyphylline | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Minor | 0 | [
[
[
523,
23,
746
]
],
[
[
523,
62,
1031
],
[
1031,
1,
746
]
],
[
[
523,
21,
29118
],
[
29118,
60,
746
]
],
[
[
523,
1,
902
],
[
902,
23,
746
]
],
[
[
523,
1,
1418
],
[
1418,
62,
746
]
],
[
[
523,
40,
1382
],
[
1382,
62,
746
]
],
[
[
523,
40,
1119
],
[
1119,
23,
746
]
],
[
[
523,
62,
1031
],
[
1031,
1,
11717
],
[
11717,
40,
746
]
],
[
[
523,
21,
29118
],
[
29118,
60,
1031
],
[
1031,
1,
746
]
],
[
[
523,
21,
28702
],
[
28702,
60,
1418
],
[
1418,
62,
746
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Theobromine"
],
[
"Theobromine",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Theophylline"
],
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
]
],
[
[
"Alprazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Muscle twitching"
],
[
"Muscle twitching",
"{u} (Side Effect) is caused by {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dyphylline"
]
]
] | Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline (Compound) resembles Dyphylline (Compound)
Alprazolam (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Dyphylline (Compound)
Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Alprazolam (Compound) resembles Estazolam (Compound) and Estazolam may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Alprazolam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline (Compound) resembles Theobromine (Compound) and Theobromine (Compound) resembles Dyphylline (Compound)
Alprazolam (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Theophylline (Compound) and Theophylline (Compound) resembles Dyphylline (Compound)
Alprazolam (Compound) causes Muscle twitching (Side Effect) and Muscle twitching (Side Effect) is caused by Estazolam (Compound) and Estazolam may cause a minor interaction that can limit clinical effects when taken with Dyphylline |
DB00607 | DB12010 | 1,249 | 214 | [
"DDInter1256",
"DDInter785"
] | Nafcillin | Fostamatinib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
1249,
24,
214
]
],
[
[
1249,
24,
976
],
[
976,
24,
214
]
],
[
[
1249,
25,
866
],
[
866,
24,
214
]
],
[
[
1249,
63,
597
],
[
597,
24,
214
]
],
[
[
1249,
24,
676
],
[
676,
63,
214
]
],
[
[
1249,
25,
1017
],
[
1017,
63,
214
]
],
[
[
1249,
62,
168
],
[
168,
24,
214
]
],
[
[
1249,
64,
663
],
[
663,
24,
214
]
],
[
[
1249,
23,
609
],
[
609,
25,
214
]
],
[
[
1249,
24,
129
],
[
129,
25,
214
]
]
] | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fostamatinib |
DB00344 | DB06663 | 1,302 | 1,154 | [
"DDInter1543",
"DDInter1398"
] | Protriptyline | Pasireotide | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1302,
25,
1154
]
],
[
[
1302,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
1302,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1302,
23,
112
],
[
112,
23,
1154
]
],
[
[
1302,
24,
959
],
[
959,
24,
1154
]
],
[
[
1302,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
1302,
63,
245
],
[
245,
24,
1154
]
],
[
[
1302,
64,
702
],
[
702,
25,
1154
]
],
[
[
1302,
25,
1494
],
[
1494,
25,
1154
]
],
[
[
1302,
25,
1011
],
[
1011,
64,
1154
]
]
] | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
] | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Protriptyline (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Protriptyline may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Pasireotide
Protriptyline may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Pasireotide
Protriptyline may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Pasireotide |
DB00295 | DB00902 | 475 | 104 | [
"DDInter1244",
"DDInter1168"
] | Morphine | Methdilazine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
475,
24,
104
]
],
[
[
475,
24,
13
],
[
13,
24,
104
]
],
[
[
475,
24,
820
],
[
820,
1,
104
]
],
[
[
475,
24,
537
],
[
537,
40,
104
]
],
[
[
475,
25,
508
],
[
508,
1,
104
]
],
[
[
475,
24,
401
],
[
401,
63,
104
]
],
[
[
475,
25,
1216
],
[
1216,
24,
104
]
],
[
[
475,
36,
560
],
[
560,
63,
104
]
],
[
[
475,
25,
1053
],
[
1053,
63,
104
]
],
[
[
475,
23,
22
],
[
22,
63,
104
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Morphine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound)
Morphine may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Methdilazine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Morphine may lead to a major life threatening interaction when taken with Flurazepam and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Morphine (Compound) resembles Oxymorphone (Compound) and Morphine may lead to a major life threatening interaction when taken with Oxymorphone and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Morphine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Morphine may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine |
DB00252 | DB00539 | 362 | 11 | [
"DDInter1460",
"DDInter1837"
] | Phenytoin | Toremifene | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Major | 2 | [
[
[
362,
25,
11
]
],
[
[
362,
24,
1594
],
[
1594,
40,
11
]
],
[
[
362,
1,
11234
],
[
11234,
40,
11
]
],
[
[
362,
35,
1376
],
[
1376,
40,
11
]
],
[
[
362,
6,
4973
],
[
4973,
45,
11
]
],
[
[
362,
7,
6952
],
[
6952,
46,
11
]
],
[
[
362,
18,
17148
],
[
17148,
57,
11
]
],
[
[
362,
21,
28936
],
[
28936,
60,
11
]
],
[
[
362,
24,
112
],
[
112,
62,
11
]
],
[
[
362,
24,
723
],
[
723,
63,
11
]
]
] | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl Benzoate"
],
[
"Benzyl Benzoate",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) downregulates {v} (Gene)",
"ZDHHC6"
],
[
"ZDHHC6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Toremifene"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
]
] | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Toremifene (Compound)
Phenytoin (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Toremifene (Compound)
Phenytoin (Compound) resembles Diphenhydramine (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Toremifene (Compound)
Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Phenytoin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Toremifene (Compound)
Phenytoin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Toremifene (Compound)
Phenytoin (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Toremifene (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene |
DB00726 | DB11986 | 1,164 | 484 | [
"DDInter1876",
"DDInter648"
] | Trimipramine | Entrectinib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
1164,
24,
484
]
],
[
[
1164,
23,
112
],
[
112,
23,
484
]
],
[
[
1164,
25,
222
],
[
222,
23,
484
]
],
[
[
1164,
24,
774
],
[
774,
24,
484
]
],
[
[
1164,
63,
322
],
[
322,
24,
484
]
],
[
[
1164,
1,
216
],
[
216,
24,
484
]
],
[
[
1164,
25,
1133
],
[
1133,
24,
484
]
],
[
[
1164,
24,
1476
],
[
1476,
63,
484
]
],
[
[
1164,
35,
820
],
[
820,
24,
484
]
],
[
[
1164,
64,
1494
],
[
1494,
24,
484
]
]
] | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
]
] | Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Trimipramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine (Compound) resembles Alimemazine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Trimipramine may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib |
DB00314 | DB00515 | 894 | 589 | [
"DDInter288",
"DDInter387"
] | Capreomycin | Cisplatin | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Moderate | 1 | [
[
[
894,
24,
589
]
],
[
[
894,
21,
28680
],
[
28680,
60,
589
]
],
[
[
894,
24,
101
],
[
101,
63,
589
]
],
[
[
894,
24,
251
],
[
251,
24,
589
]
],
[
[
894,
25,
1132
],
[
1132,
63,
589
]
],
[
[
894,
63,
837
],
[
837,
24,
589
]
],
[
[
894,
25,
1527
],
[
1527,
64,
589
]
],
[
[
894,
21,
28680
],
[
28680,
60,
956
],
[
956,
62,
589
]
],
[
[
894,
21,
31264
],
[
31264,
60,
450
],
[
450,
63,
589
]
],
[
[
894,
21,
28678
],
[
28678,
60,
1176
],
[
1176,
23,
589
]
]
] | [
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nephrotoxicity"
],
[
"Nephrotoxicity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatocellular injury"
],
[
"Hepatocellular injury",
"{u} (Side Effect) is caused by {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cisplatin"
]
]
] | Capreomycin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Cisplatin (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Capreomycin may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Capreomycin may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Cisplatin
Capreomycin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Cisplatin
Capreomycin (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Cyclophosphamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Capreomycin (Compound) causes Hepatocellular injury (Side Effect) and Hepatocellular injury (Side Effect) is caused by Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Cisplatin |
DB00295 | DB00660 | 475 | 1,470 | [
"DDInter1244",
"DDInter1163"
] | Morphine | Metaxalone | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. | Major | 2 | [
[
[
475,
25,
1470
]
],
[
[
475,
21,
28681
],
[
28681,
60,
1470
]
],
[
[
475,
24,
537
],
[
537,
63,
1470
]
],
[
[
475,
24,
1242
],
[
1242,
24,
1470
]
],
[
[
475,
63,
1648
],
[
1648,
24,
1470
]
],
[
[
475,
25,
267
],
[
267,
63,
1470
]
],
[
[
475,
21,
28681
],
[
28681,
60,
537
],
[
537,
63,
1470
]
],
[
[
475,
21,
29119
],
[
29119,
60,
1242
],
[
1242,
24,
1470
]
],
[
[
475,
24,
537
],
[
537,
21,
28681
],
[
28681,
60,
1470
]
],
[
[
475,
24,
1219
],
[
1219,
63,
1242
],
[
1242,
24,
1470
]
]
] | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemolytic anaemia"
],
[
"Haemolytic anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metaxalone"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
]
] | Morphine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Metaxalone (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine (Compound) causes Haemolytic anaemia (Side Effect) and Haemolytic anaemia (Side Effect) is caused by Cetirizine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Metaxalone (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Metaxalone |
DB00443 | DB11110 | 251 | 603 | [
"DDInter195",
"DDInter1115"
] | Betamethasone | Magnesium citrate | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
251,
24,
603
]
],
[
[
251,
24,
789
],
[
789,
24,
603
]
],
[
[
251,
25,
246
],
[
246,
24,
603
]
],
[
[
251,
63,
494
],
[
494,
24,
603
]
],
[
[
251,
40,
870
],
[
870,
24,
603
]
],
[
[
251,
64,
1176
],
[
1176,
24,
603
]
],
[
[
251,
1,
1486
],
[
1486,
24,
603
]
],
[
[
251,
23,
688
],
[
688,
24,
603
]
],
[
[
251,
24,
1375
],
[
1375,
63,
603
]
],
[
[
251,
25,
255
],
[
255,
63,
603
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Betamethasone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB00668 | DB00867 | 874 | 1,052 | [
"DDInter652",
"DDInter1606"
] | Epinephrine | Ritodrine | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades,,. On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
874,
24,
1052
]
],
[
[
874,
40,
1188
],
[
1188,
1,
1052
]
],
[
[
874,
64,
1523
],
[
1523,
40,
1052
]
],
[
[
874,
6,
3576
],
[
3576,
45,
1052
]
],
[
[
874,
7,
3422
],
[
3422,
46,
1052
]
],
[
[
874,
24,
1148
],
[
1148,
63,
1052
]
],
[
[
874,
63,
1466
],
[
1466,
24,
1052
]
],
[
[
874,
24,
1144
],
[
1144,
24,
1052
]
],
[
[
874,
25,
1264
],
[
1264,
63,
1052
]
],
[
[
874,
40,
1636
],
[
1636,
24,
1052
]
]
] | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Arbutamine"
],
[
"Arbutamine",
"{u} (Compound) resembles {v} (Compound)",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound)",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
]
] | Epinephrine (Compound) resembles Arbutamine (Compound) and Arbutamine (Compound) resembles Ritodrine (Compound)
Epinephrine may lead to a major life threatening interaction when taken with Labetalol and Labetalol (Compound) resembles Ritodrine (Compound)
Epinephrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Ritodrine (Compound)
Epinephrine (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Ritodrine (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Epinephrine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Epinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine |
DB01181 | DB09117 | 1,532 | 957 | [
"DDInter906",
"DDInter1391"
] | Ifosfamide | Paraldehyde | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect. | Moderate | 1 | [
[
[
1532,
24,
957
]
],
[
[
1532,
63,
126
],
[
126,
23,
957
]
],
[
[
1532,
63,
1264
],
[
1264,
24,
957
]
],
[
[
1532,
64,
770
],
[
770,
24,
957
]
],
[
[
1532,
24,
516
],
[
516,
24,
957
]
],
[
[
1532,
24,
407
],
[
407,
63,
957
]
],
[
[
1532,
63,
475
],
[
475,
25,
957
]
],
[
[
1532,
63,
126
],
[
126,
24,
1264
],
[
1264,
24,
957
]
],
[
[
1532,
63,
1264
],
[
1264,
63,
126
],
[
126,
23,
957
]
],
[
[
1532,
64,
770
],
[
770,
24,
1264
],
[
1264,
24,
957
]
]
] | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paraldehyde"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
]
] | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Ifosfamide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde
Ifosfamide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde |
DB00317 | DB08903 | 883 | 996 | [
"DDInter810",
"DDInter170"
] | Gefitinib | Bedaquiline | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Moderate | 1 | [
[
[
883,
24,
996
]
],
[
[
883,
6,
8374
],
[
8374,
45,
996
]
],
[
[
883,
21,
29282
],
[
29282,
60,
996
]
],
[
[
883,
40,
26
],
[
26,
63,
996
]
],
[
[
883,
24,
1613
],
[
1613,
63,
996
]
],
[
[
883,
24,
353
],
[
353,
24,
996
]
],
[
[
883,
63,
912
],
[
912,
24,
996
]
],
[
[
883,
40,
1195
],
[
1195,
24,
996
]
],
[
[
883,
24,
609
],
[
609,
25,
996
]
],
[
[
883,
25,
1377
],
[
1377,
25,
996
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Gefitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
]
] | Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Gefitinib (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Gefitinib (Compound) resembles Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Gefitinib (Compound) resembles Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Bedaquiline
Gefitinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bedaquiline |
DB00685 | DB00992 | 1,299 | 842 | [
"DDInter1887",
"DDInter1182"
] | Trovafloxacin | Methyl aminolevulinate (topical) | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. | Moderate | 1 | [
[
[
1299,
24,
842
]
],
[
[
1299,
21,
29360
],
[
29360,
60,
842
]
],
[
[
1299,
24,
1274
],
[
1274,
24,
842
]
],
[
[
1299,
63,
663
],
[
663,
24,
842
]
],
[
[
1299,
64,
1101
],
[
1101,
24,
842
]
],
[
[
1299,
24,
848
],
[
848,
63,
842
]
],
[
[
1299,
1,
872
],
[
872,
63,
842
]
],
[
[
1299,
1,
1467
],
[
1467,
24,
842
]
],
[
[
1299,
25,
213
],
[
213,
36,
842
]
],
[
[
1299,
21,
29360
],
[
29360,
60,
246
],
[
246,
63,
842
]
]
] | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Face oedema"
],
[
"Face oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Face oedema"
],
[
"Face oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
]
] | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Methyl aminolevulinate (Compound)
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Trovafloxacin may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate
Trovafloxacin (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate |
DB00078 | DB11166 | 1,172 | 18 | [
"DDInter898",
"DDInter104"
] | Ibritumomab tiuxetan | Antithrombin Alfa | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Major | 2 | [
[
[
1172,
25,
18
]
],
[
[
1172,
25,
714
],
[
714,
24,
18
]
],
[
[
1172,
24,
738
],
[
738,
63,
18
]
],
[
[
1172,
37,
1274
],
[
1274,
24,
18
]
],
[
[
1172,
24,
1039
],
[
1039,
24,
18
]
],
[
[
1172,
25,
1409
],
[
1409,
25,
18
]
],
[
[
1172,
25,
1421
],
[
1421,
64,
18
]
],
[
[
1172,
64,
834
],
[
834,
25,
18
]
],
[
[
1172,
25,
714
],
[
714,
63,
1595
],
[
1595,
24,
18
]
],
[
[
1172,
25,
848
],
[
848,
24,
714
],
[
714,
24,
18
]
]
] | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
]
] | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa |
DB09054 | DB11703 | 384 | 405 | [
"DDInter905",
"DDInter9"
] | Idelalisib | Acalabrutinib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
384,
25,
405
]
],
[
[
384,
63,
1051
],
[
1051,
24,
405
]
],
[
[
384,
25,
951
],
[
951,
24,
405
]
],
[
[
384,
25,
982
],
[
982,
63,
405
]
],
[
[
384,
64,
1313
],
[
1313,
24,
405
]
],
[
[
384,
24,
151
],
[
151,
63,
405
]
],
[
[
384,
62,
1230
],
[
1230,
24,
405
]
],
[
[
384,
24,
810
],
[
810,
24,
405
]
],
[
[
384,
63,
804
],
[
804,
25,
405
]
],
[
[
384,
64,
463
],
[
463,
25,
405
]
]
] | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
],
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
],
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
]
] | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may lead to a major life threatening interaction when taken with Suvorexant and Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone may lead to a major life threatening interaction when taken with Acalabrutinib
Idelalisib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may lead to a major life threatening interaction when taken with Acalabrutinib |
DB00222 | DB06016 | 245 | 1,508 | [
"DDInter825",
"DDInter300"
] | Glimepiride | Cariprazine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198] | Moderate | 1 | [
[
[
245,
24,
1508
]
],
[
[
245,
64,
600
],
[
600,
24,
1508
]
],
[
[
245,
63,
176
],
[
176,
24,
1508
]
],
[
[
245,
24,
1450
],
[
1450,
63,
1508
]
],
[
[
245,
24,
1101
],
[
1101,
24,
1508
]
],
[
[
245,
40,
1411
],
[
1411,
24,
1508
]
],
[
[
245,
25,
86
],
[
86,
24,
1508
]
],
[
[
245,
23,
1051
],
[
1051,
24,
1508
]
],
[
[
245,
24,
609
],
[
609,
25,
1508
]
],
[
[
245,
64,
600
],
[
600,
25,
1593
],
[
1593,
63,
1508
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cariprazine"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
]
] | Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may lead to a major life threatening interaction when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Cariprazine
Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine |
DB01110 | DB11581 | 86 | 1,456 | [
"DDInter1209",
"DDInter1926"
] | Miconazole | Venetoclax | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion . | Moderate | 1 | [
[
[
86,
24,
1456
]
],
[
[
86,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
86,
23,
466
],
[
466,
63,
1456
]
],
[
[
86,
62,
1413
],
[
1413,
24,
1456
]
],
[
[
86,
24,
594
],
[
594,
24,
1456
]
],
[
[
86,
64,
126
],
[
126,
24,
1456
]
],
[
[
86,
23,
1204
],
[
1204,
24,
1456
]
],
[
[
86,
63,
529
],
[
529,
24,
1456
]
],
[
[
86,
63,
915
],
[
915,
25,
1456
]
],
[
[
86,
24,
1017
],
[
1017,
64,
1456
]
]
] | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ambrisentan"
],
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
]
] | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a minor interaction that can limit clinical effects when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan and Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Venetoclax
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax |
DB00060 | DB00744 | 912 | 1,288 | [
"DDInter947",
"DDInter1962"
] | Interferon beta-1a | Zileuton | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. | Moderate | 1 | [
[
[
912,
24,
1288
]
],
[
[
912,
24,
482
],
[
482,
24,
1288
]
],
[
[
912,
63,
305
],
[
305,
24,
1288
]
],
[
[
912,
24,
187
],
[
187,
63,
1288
]
],
[
[
912,
25,
1510
],
[
1510,
64,
1288
]
],
[
[
912,
24,
482
],
[
482,
21,
28826
],
[
28826,
60,
1288
]
],
[
[
912,
63,
305
],
[
305,
24,
482
],
[
482,
24,
1288
]
],
[
[
912,
24,
187
],
[
187,
25,
1297
],
[
1297,
63,
1288
]
],
[
[
912,
24,
1324
],
[
1324,
24,
1297
],
[
1297,
63,
1288
]
],
[
[
912,
24,
283
],
[
283,
63,
1297
],
[
1297,
63,
1288
]
]
] | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
]
] | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Zileuton (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton |
DB00376 | DB01278 | 1,105 | 1,021 | [
"DDInter1870",
"DDInter1506"
] | Trihexyphenidyl | Pramlintide | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa]. Trihexyphenidyl was granted FDA approval on 13 May 1949. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1105,
24,
1021
]
],
[
[
1105,
24,
1507
],
[
1507,
24,
1021
]
],
[
[
1105,
40,
456
],
[
456,
24,
1021
]
],
[
[
1105,
35,
1192
],
[
1192,
24,
1021
]
],
[
[
1105,
63,
352
],
[
352,
24,
1021
]
],
[
[
1105,
1,
1386
],
[
1386,
24,
1021
]
],
[
[
1105,
24,
1511
],
[
1511,
63,
1021
]
],
[
[
1105,
24,
1507
],
[
1507,
24,
1536
],
[
1536,
63,
1021
]
],
[
[
1105,
40,
456
],
[
456,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
1105,
24,
543
],
[
543,
63,
839
],
[
839,
24,
1021
]
]
] | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Procyclidine"
],
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
],
[
"Belladonna",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
]
] | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl (Compound) resembles Glycopyrronium (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl (Compound) resembles Procyclidine (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
DB00704 | DB01299 | 267 | 698 | [
"DDInter1263",
"DDInter1722"
] | Naltrexone | Sulfadoxine | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
267,
24,
698
]
],
[
[
267,
24,
1247
],
[
1247,
40,
698
]
],
[
[
267,
63,
1029
],
[
1029,
40,
698
]
],
[
[
267,
63,
161
],
[
161,
1,
698
]
],
[
[
267,
63,
1560
],
[
1560,
24,
698
]
],
[
[
267,
24,
1613
],
[
1613,
63,
698
]
],
[
[
267,
24,
1247
],
[
1247,
40,
11462
],
[
11462,
40,
698
]
],
[
[
267,
63,
1029
],
[
1029,
1,
11462
],
[
11462,
40,
698
]
],
[
[
267,
63,
1560
],
[
1560,
24,
1247
],
[
1247,
40,
698
]
],
[
[
267,
24,
1613
],
[
1613,
63,
1247
],
[
1247,
40,
698
]
]
] | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethazine"
],
[
"Sulfamethazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethazine"
],
[
"Sulfamethazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadoxine"
]
]
] | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfadoxine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadoxine
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfamethazine (Compound) and Sulfamethazine (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethazine (Compound) and Sulfamethazine (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound) |
DB11986 | DB14761 | 484 | 242 | [
"DDInter648",
"DDInter1578"
] | Entrectinib | Remdesivir | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020. | Moderate | 1 | [
[
[
484,
24,
242
]
],
[
[
484,
63,
467
],
[
467,
24,
242
]
],
[
[
484,
64,
1377
],
[
1377,
24,
242
]
],
[
[
484,
24,
971
],
[
971,
24,
242
]
],
[
[
484,
25,
283
],
[
283,
24,
242
]
],
[
[
484,
64,
1487
],
[
1487,
25,
242
]
],
[
[
484,
63,
467
],
[
467,
25,
1377
],
[
1377,
24,
242
]
],
[
[
484,
64,
1377
],
[
1377,
25,
1130
],
[
1130,
24,
242
]
],
[
[
484,
64,
129
],
[
129,
63,
467
],
[
467,
24,
242
]
],
[
[
484,
63,
482
],
[
482,
24,
1130
],
[
1130,
24,
242
]
]
] | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
]
] | Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir |
DB00765 | DB11130 | 1,266 | 407 | [
"DDInter1205",
"DDInter1344"
] | Metyrosine | Opium | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
1266,
24,
407
]
],
[
[
1266,
63,
662
],
[
662,
24,
407
]
],
[
[
1266,
24,
104
],
[
104,
24,
407
]
],
[
[
1266,
24,
1609
],
[
1609,
63,
407
]
],
[
[
1266,
63,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
],
[
[
1266,
24,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
1266,
24,
849
],
[
849,
63,
409
],
[
409,
24,
407
]
],
[
[
1266,
63,
1594
],
[
1594,
24,
558
],
[
558,
24,
407
]
],
[
[
1266,
40,
848
],
[
848,
40,
1053
],
[
1053,
25,
407
]
],
[
[
1266,
63,
475
],
[
475,
25,
558
],
[
558,
24,
407
]
]
] | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} (Compound) resembles {v} (Compound)",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metyrosine (Compound) resembles Ibuprofen (Compound) and Ibuprofen (Compound) resembles Procarbazine (Compound) and Procarbazine may lead to a major life threatening interaction when taken with Opium
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00250 | DB06608 | 10 | 1,185 | [
"DDInter475",
"DDInter1739"
] | Dapsone | Tafenoquine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture. It was FDA approved on July 20, 2018. | Moderate | 1 | [
[
[
10,
24,
1185
]
],
[
[
10,
25,
490
],
[
490,
25,
1185
]
],
[
[
10,
25,
1455
],
[
1455,
64,
1185
]
],
[
[
10,
25,
490
],
[
490,
25,
1455
],
[
1455,
64,
1185
]
],
[
[
10,
6,
10215
],
[
10215,
45,
1364
],
[
1364,
24,
1185
]
],
[
[
10,
25,
1455
],
[
1455,
63,
1364
],
[
1364,
24,
1185
]
],
[
[
10,
25,
1455
],
[
1455,
64,
490
],
[
490,
25,
1185
]
],
[
[
10,
21,
28817
],
[
28817,
60,
1364
],
[
1364,
24,
1185
]
],
[
[
10,
6,
8374
],
[
8374,
45,
228
],
[
228,
25,
1185
]
],
[
[
10,
21,
28817
],
[
28817,
60,
490
],
[
490,
25,
1185
]
]
] | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Guanfacine"
],
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
],
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Guanfacine"
],
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dofetilide"
],
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prilocaine"
],
[
"Prilocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafenoquine"
]
]
] | Dapsone may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may lead to a major life threatening interaction when taken with Tafenoquine
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Tafenoquine
Dapsone may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Tafenoquine
Dapsone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Dapsone may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may lead to a major life threatening interaction when taken with Tafenoquine
Dapsone (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Guanfacine (Compound) and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Tafenoquine
Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dofetilide (Compound) and Dofetilide may lead to a major life threatening interaction when taken with Tafenoquine
Dapsone (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Prilocaine (Compound) and Prilocaine may lead to a major life threatening interaction when taken with Tafenoquine |
DB05015 | DB08886 | 1,077 | 637 | [
"DDInter174",
"DDInter126"
] | Belinostat | Asparaginase Erwinia chrysanthemi | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
1077,
24,
637
]
],
[
[
1077,
24,
850
],
[
850,
24,
637
]
],
[
[
1077,
63,
267
],
[
267,
24,
637
]
],
[
[
1077,
24,
292
],
[
292,
63,
637
]
],
[
[
1077,
64,
581
],
[
581,
24,
637
]
],
[
[
1077,
25,
1510
],
[
1510,
25,
637
]
],
[
[
1077,
64,
1377
],
[
1377,
25,
637
]
],
[
[
1077,
24,
850
],
[
850,
63,
640
],
[
640,
24,
637
]
],
[
[
1077,
63,
267
],
[
267,
63,
640
],
[
640,
24,
637
]
],
[
[
1077,
63,
79
],
[
79,
24,
392
],
[
392,
24,
637
]
]
] | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Belinostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00099 | DB00570 | 440 | 147 | [
"DDInter735",
"DDInter1936"
] | Filgrastim | Vinblastine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
440,
24,
147
]
],
[
[
440,
24,
134
],
[
134,
24,
147
]
],
[
[
440,
24,
970
],
[
970,
23,
147
]
],
[
[
440,
24,
37
],
[
37,
62,
147
]
],
[
[
440,
24,
995
],
[
995,
63,
147
]
],
[
[
440,
63,
367
],
[
367,
24,
147
]
],
[
[
440,
25,
1064
],
[
1064,
25,
147
]
],
[
[
440,
24,
384
],
[
384,
64,
147
]
],
[
[
440,
63,
1648
],
[
1648,
25,
147
]
],
[
[
440,
24,
134
],
[
134,
40,
11503
],
[
11503,
40,
147
]
]
] | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
],
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} (Compound) resembles {v} (Compound)",
"Vindesine"
],
[
"Vindesine",
"{u} (Compound) resembles {v} (Compound)",
"Vinblastine"
]
]
] | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Filgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Vinblastine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vindesine (Compound) and Vindesine (Compound) resembles Vinblastine (Compound) |
DB01229 | DB14840 | 973 | 861 | [
"DDInter1377",
"DDInter1601"
] | Paclitaxel | Ripretinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors. | Moderate | 1 | [
[
[
973,
24,
861
]
],
[
[
973,
24,
351
],
[
351,
24,
861
]
],
[
[
973,
63,
353
],
[
353,
24,
861
]
],
[
[
973,
24,
384
],
[
384,
25,
861
]
],
[
[
973,
63,
609
],
[
609,
25,
861
]
],
[
[
973,
24,
351
],
[
351,
24,
214
],
[
214,
24,
861
]
],
[
[
973,
24,
214
],
[
214,
63,
351
],
[
351,
24,
861
]
],
[
[
973,
63,
353
],
[
353,
24,
351
],
[
351,
24,
861
]
],
[
[
973,
24,
392
],
[
392,
25,
351
],
[
351,
24,
861
]
],
[
[
973,
63,
918
],
[
918,
25,
351
],
[
351,
24,
861
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib |
DB00626 | DB01265 | 1,441 | 1,477 | [
"DDInter161",
"DDInter1757"
] | Bacitracin | Telbivudine | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748] | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
1441,
24,
1477
]
],
[
[
1441,
21,
28719
],
[
28719,
60,
1477
]
],
[
[
1441,
25,
629
],
[
629,
24,
1477
]
],
[
[
1441,
63,
1555
],
[
1555,
24,
1477
]
],
[
[
1441,
24,
712
],
[
712,
24,
1477
]
],
[
[
1441,
40,
1481
],
[
1481,
24,
1477
]
],
[
[
1441,
21,
28719
],
[
28719,
60,
1083
],
[
1083,
1,
1477
]
],
[
[
1441,
21,
28787
],
[
28787,
60,
903
],
[
903,
40,
1477
]
],
[
[
1441,
25,
629
],
[
629,
63,
139
],
[
139,
1,
1477
]
],
[
[
1441,
25,
1132
],
[
1132,
21,
28745
],
[
28745,
60,
1477
]
]
] | [
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
],
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trifluridine"
],
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Decitabine"
],
[
"Decitabine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telbivudine"
]
]
] | Bacitracin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Telbivudine (Compound)
Bacitracin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Bacitracin (Compound) resembles Polymyxin B (Compound) and Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Bacitracin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Trifluridine (Compound) and Trifluridine (Compound) resembles Telbivudine (Compound)
Bacitracin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Decitabine (Compound) and Decitabine (Compound) resembles Telbivudine (Compound)
Bacitracin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Bacitracin may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound) |
DB00191 | DB00454 | 73 | 1,349 | [
"DDInter1447",
"DDInter1150"
] | Phentermine | Meperidine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Moderate | 1 | [
[
[
73,
24,
1349
]
],
[
[
73,
25,
901
],
[
901,
1,
1349
]
],
[
[
73,
24,
411
],
[
411,
1,
1349
]
],
[
[
73,
6,
7390
],
[
7390,
45,
1349
]
],
[
[
73,
21,
28779
],
[
28779,
60,
1349
]
],
[
[
73,
24,
820
],
[
820,
63,
1349
]
],
[
[
73,
24,
1503
],
[
1503,
24,
1349
]
],
[
[
73,
25,
1039
],
[
1039,
64,
1349
]
],
[
[
73,
24,
1264
],
[
1264,
64,
1349
]
],
[
[
73,
25,
901
],
[
901,
40,
41
],
[
41,
1,
1349
]
]
] | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
[
"Remifentanil",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meperidine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
]
]
] | Phentermine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Meperidine (Compound)
Phentermine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Meperidine (Compound)
Phentermine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Meperidine (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Meperidine
Phentermine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Meperidine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Meperidine
Phentermine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Meperidine (Compound) |
DB00705 | DB00969 | 441 | 2 | [
"DDInter496",
"DDInter52"
] | Delavirdine | Alosetron | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. | Moderate | 1 | [
[
[
441,
24,
2
]
],
[
[
441,
6,
6017
],
[
6017,
45,
2
]
],
[
[
441,
21,
28883
],
[
28883,
60,
2
]
],
[
[
441,
25,
1362
],
[
1362,
63,
2
]
],
[
[
441,
63,
752
],
[
752,
24,
2
]
],
[
[
441,
24,
1619
],
[
1619,
63,
2
]
],
[
[
441,
6,
6017
],
[
6017,
45,
44
],
[
44,
40,
2
]
],
[
[
441,
21,
28883
],
[
28883,
60,
44
],
[
44,
40,
2
]
],
[
[
441,
21,
28826
],
[
28826,
60,
1622
],
[
1622,
24,
2
]
],
[
[
441,
21,
30362
],
[
30362,
60,
875
],
[
875,
63,
2
]
]
] | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Ondansetron"
],
[
"Ondansetron",
"{u} (Compound) resembles {v} (Compound)",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ondansetron"
],
[
"Ondansetron",
"{u} (Compound) resembles {v} (Compound)",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Delavirdine",
"{u} (Compound) causes {v} (Side Effect)",
"Cognitive disorder"
],
[
"Cognitive disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
]
] | Delavirdine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound)
Delavirdine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Alosetron (Compound)
Delavirdine may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Alosetron
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Alosetron
Delavirdine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ondansetron (Compound) and Ondansetron (Compound) resembles Alosetron (Compound)
Delavirdine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ondansetron (Compound) and Ondansetron (Compound) resembles Alosetron (Compound)
Delavirdine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Alosetron
Delavirdine (Compound) causes Cognitive disorder (Side Effect) and Cognitive disorder (Side Effect) is caused by Fosaprepitant (Compound) and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Alosetron |
DB00176 | DB09030 | 529 | 840 | [
"DDInter770",
"DDInter1945"
] | Fluvoxamine | Vorapaxar | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. | Moderate | 1 | [
[
[
529,
24,
840
]
],
[
[
529,
24,
885
],
[
885,
24,
840
]
],
[
[
529,
24,
1017
],
[
1017,
63,
840
]
],
[
[
529,
25,
1039
],
[
1039,
24,
840
]
],
[
[
529,
24,
702
],
[
702,
25,
840
]
],
[
[
529,
63,
273
],
[
273,
25,
840
]
],
[
[
529,
24,
760
],
[
760,
64,
840
]
],
[
[
529,
25,
39
],
[
39,
25,
840
]
],
[
[
529,
24,
885
],
[
885,
23,
944
],
[
944,
62,
840
]
],
[
[
529,
24,
1017
],
[
1017,
64,
1496
],
[
1496,
63,
840
]
]
] | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
],
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
]
] | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fluvoxamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Vorapaxar
Fluvoxamine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar |
DB01255 | DB08938 | 633 | 1,384 | [
"DDInter1078",
"DDInter1112"
] | Lisdexamfetamine | Magaldrate | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
633,
24,
1384
]
],
[
[
633,
1,
1523
],
[
1523,
23,
1384
]
],
[
[
633,
40,
743
],
[
743,
23,
1384
]
],
[
[
633,
63,
401
],
[
401,
23,
1384
]
],
[
[
633,
40,
1529
],
[
1529,
24,
1384
]
],
[
[
633,
25,
478
],
[
478,
24,
1384
]
],
[
[
633,
1,
80
],
[
80,
24,
1384
]
],
[
[
633,
24,
28
],
[
28,
63,
1384
]
],
[
[
633,
63,
542
],
[
542,
24,
1384
]
],
[
[
633,
24,
594
],
[
594,
24,
1384
]
]
] | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
]
] | Lisdexamfetamine (Compound) resembles Labetalol (Compound) and Labetalol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Lisdexamfetamine (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Lisdexamfetamine (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Lisdexamfetamine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Lisdexamfetamine (Compound) resembles Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate |
DB01001 | DB01044 | 688 | 246 | [
"DDInter1632",
"DDInter809"
] | Salbutamol | Gatifloxacin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Moderate | 1 | [
[
[
688,
24,
246
]
],
[
[
688,
63,
739
],
[
739,
1,
246
]
],
[
[
688,
24,
945
],
[
945,
40,
246
]
],
[
[
688,
21,
28868
],
[
28868,
60,
246
]
],
[
[
688,
24,
1053
],
[
1053,
62,
246
]
],
[
[
688,
62,
112
],
[
112,
23,
246
]
],
[
[
688,
24,
603
],
[
603,
63,
246
]
],
[
[
688,
63,
1559
],
[
1559,
24,
246
]
],
[
[
688,
63,
51
],
[
51,
25,
246
]
],
[
[
688,
62,
251
],
[
251,
25,
246
]
]
] | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
]
] | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Compound)
Salbutamol (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Gatifloxacin (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Gatifloxacin
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Gatifloxacin |
DB00427 | DB00490 | 1,233 | 946 | [
"DDInter1879",
"DDInter254"
] | Triprolidine | Buspirone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety. It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate. The potential use of buspirone in combination with [melatonin] in depression and cognitive impairment via promoting neurogenesis has also been investigated. | Moderate | 1 | [
[
[
1233,
24,
946
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
946
]
],
[
[
1233,
63,
1242
],
[
1242,
24,
946
]
],
[
[
1233,
24,
820
],
[
820,
63,
946
]
],
[
[
1233,
24,
1614
],
[
1614,
24,
946
]
],
[
[
1233,
24,
222
],
[
222,
64,
946
]
],
[
[
1233,
63,
475
],
[
475,
25,
946
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
86
],
[
86,
63,
946
]
],
[
[
1233,
63,
1242
],
[
1242,
21,
29081
],
[
29081,
60,
946
]
],
[
[
1233,
24,
820
],
[
820,
6,
8374
],
[
8374,
45,
946
]
]
] | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Buspirone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Buspirone"
]
]
] | Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Buspirone (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Buspirone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Buspirone
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Buspirone (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Buspirone (Compound) |
DB00023 | DB01309 | 305 | 1,254 | [
"DDInter127",
"DDInter933"
] | Asparaginase Escherichia coli | Insulin glulisine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
305,
24,
1254
]
],
[
[
305,
24,
1632
],
[
1632,
63,
1254
]
],
[
[
305,
24,
1669
],
[
1669,
24,
1254
]
],
[
[
305,
25,
695
],
[
695,
24,
1254
]
],
[
[
305,
24,
1176
],
[
1176,
25,
1254
]
],
[
[
305,
24,
1632
],
[
1632,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
305,
24,
1669
],
[
1669,
1,
1545
],
[
1545,
24,
1254
]
],
[
[
305,
24,
1545
],
[
1545,
40,
1669
],
[
1669,
24,
1254
]
],
[
[
305,
24,
167
],
[
167,
24,
1603
],
[
1603,
24,
1254
]
],
[
[
305,
24,
1603
],
[
1603,
64,
1621
],
[
1621,
23,
1254
]
]
] | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicotinamide"
],
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicotinamide"
],
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
[
"Captopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin glulisine"
]
]
] | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide and Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Nicotinamide and Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine |
DB08901 | DB12095 | 1,468 | 179 | [
"DDInter1492",
"DDInter1760"
] | Ponatinib | Telotristat ethyl | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease. | Moderate | 1 | [
[
[
1468,
24,
179
]
],
[
[
1468,
63,
310
],
[
310,
24,
179
]
],
[
[
1468,
24,
214
],
[
214,
24,
179
]
],
[
[
1468,
64,
1213
],
[
1213,
24,
179
]
],
[
[
1468,
25,
283
],
[
283,
63,
179
]
],
[
[
1468,
74,
1419
],
[
1419,
24,
179
]
],
[
[
1468,
24,
971
],
[
971,
63,
179
]
],
[
[
1468,
25,
405
],
[
405,
24,
179
]
],
[
[
1468,
23,
1135
],
[
1135,
24,
179
]
],
[
[
1468,
24,
1476
],
[
1476,
64,
179
]
]
] | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telotristat ethyl"
]
]
] | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib (Compound) resembles Imatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Telotristat ethyl |
DB00862 | DB12267 | 1,005 | 1,476 | [
"DDInter1918",
"DDInter233"
] | Vardenafil | Brigatinib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis of cGMP in the smooth muscle cells of the corpus cavernosum. PDE5 inhibitors, such as vardenafil, inhibit the degradation of cGMP and allow increased blood flow into the penis, resulting in an erection.[A258303,L45563,L45568]. Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. The FDA approved the use of v | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1005,
24,
1476
]
],
[
[
1005,
24,
951
],
[
951,
24,
1476
]
],
[
[
1005,
63,
79
],
[
79,
24,
1476
]
],
[
[
1005,
25,
478
],
[
478,
24,
1476
]
],
[
[
1005,
25,
982
],
[
982,
63,
1476
]
],
[
[
1005,
64,
1425
],
[
1425,
24,
1476
]
],
[
[
1005,
24,
1619
],
[
1619,
63,
1476
]
],
[
[
1005,
24,
129
],
[
129,
25,
1476
]
],
[
[
1005,
63,
600
],
[
600,
25,
1476
]
],
[
[
1005,
25,
1011
],
[
1011,
25,
1476
]
]
] | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may lead to a major life threatening interaction when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Brigatinib
Vardenafil may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Brigatinib |
DB00731 | DB09100 | 1,144 | 320 | [
"DDInter1269",
"DDInter1799"
] | Nateglinide | Thyroid, porcine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA. | Moderate | 1 | [
[
[
1144,
24,
320
]
],
[
[
1144,
63,
417
],
[
417,
23,
320
]
],
[
[
1144,
24,
135
],
[
135,
24,
320
]
],
[
[
1144,
63,
73
],
[
73,
24,
320
]
],
[
[
1144,
24,
433
],
[
433,
63,
320
]
],
[
[
1144,
63,
417
],
[
417,
24,
127
],
[
127,
24,
320
]
],
[
[
1144,
24,
135
],
[
135,
63,
417
],
[
417,
23,
320
]
],
[
[
1144,
63,
1419
],
[
1419,
24,
467
],
[
467,
23,
320
]
],
[
[
1144,
24,
1445
],
[
1445,
63,
127
],
[
127,
24,
320
]
],
[
[
1144,
63,
121
],
[
121,
63,
127
],
[
127,
24,
320
]
]
] | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
]
] | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine |
DB00619 | DB00980 | 1,419 | 969 | [
"DDInter909",
"DDInter1564"
] | Imatinib | Ramelteon | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1419,
24,
969
]
],
[
[
1419,
6,
7950
],
[
7950,
45,
969
]
],
[
[
1419,
21,
28714
],
[
28714,
60,
969
]
],
[
[
1419,
24,
1619
],
[
1619,
63,
969
]
],
[
[
1419,
63,
1324
],
[
1324,
24,
969
]
],
[
[
1419,
24,
1144
],
[
1144,
24,
969
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
969
]
],
[
[
1419,
25,
982
],
[
982,
63,
969
]
],
[
[
1419,
23,
222
],
[
222,
63,
969
]
],
[
[
1419,
63,
475
],
[
475,
25,
969
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramelteon"
]
]
] | Imatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ramelteon (Compound)
Imatinib (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Ramelteon |
DB00443 | DB00877 | 251 | 629 | [
"DDInter195",
"DDInter1678"
] | Betamethasone | Sirolimus | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
251,
24,
629
]
],
[
[
251,
6,
4973
],
[
4973,
45,
629
]
],
[
[
251,
18,
2493
],
[
2493,
46,
629
]
],
[
[
251,
7,
3603
],
[
3603,
46,
629
]
],
[
[
251,
7,
9726
],
[
9726,
57,
629
]
],
[
[
251,
18,
8733
],
[
8733,
57,
629
]
],
[
[
251,
21,
29675
],
[
29675,
60,
629
]
],
[
[
251,
23,
1114
],
[
1114,
62,
629
]
],
[
[
251,
62,
1461
],
[
1461,
23,
629
]
],
[
[
251,
24,
1438
],
[
1438,
24,
629
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"HIST2H2BE"
],
[
"HIST2H2BE",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) upregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) upregulates {v} (Gene)",
"IMP3"
],
[
"IMP3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"PHGDH"
],
[
"PHGDH",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Glycosuria"
],
[
"Glycosuria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sirolimus"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
]
] | Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Betamethasone (Compound) downregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is upregulated by Sirolimus (Compound)
Betamethasone (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Sirolimus (Compound)
Betamethasone (Compound) upregulates IMP3 (Gene) and IMP3 (Gene) is downregulated by Sirolimus (Compound)
Betamethasone (Compound) downregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Sirolimus (Compound)
Betamethasone (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Sirolimus (Compound)
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Sirolimus
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sirolimus
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus |
DB00621 | DB11921 | 1,026 | 1,019 | [
"DDInter1357",
"DDInter492"
] | Oxandrolone | Deflazacort | A synthetic hormone with anabolic and androgenic properties. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
1026,
24,
1019
]
],
[
[
1026,
40,
443
],
[
443,
24,
1019
]
],
[
[
1026,
24,
959
],
[
959,
24,
1019
]
],
[
[
1026,
25,
126
],
[
126,
24,
1019
]
],
[
[
1026,
63,
1512
],
[
1512,
24,
1019
]
],
[
[
1026,
24,
1412
],
[
1412,
63,
1019
]
],
[
[
1026,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
1026,
25,
1510
],
[
1510,
25,
1019
]
],
[
[
1026,
40,
443
],
[
443,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
1026,
24,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
]
] | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
]
] | Oxandrolone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Oxandrolone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Deflazacort
Oxandrolone (Compound) resembles Spironolactone (Compound) and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort |
DB00207 | DB01142 | 1,570 | 1,264 | [
"DDInter157",
"DDInter593"
] | Azithromycin | Doxepin | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
1570,
24,
1264
]
],
[
[
1570,
24,
401
],
[
401,
24,
1264
]
],
[
[
1570,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
1570,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
1570,
23,
112
],
[
112,
23,
1264
]
],
[
[
1570,
63,
600
],
[
600,
24,
1264
]
],
[
[
1570,
24,
659
],
[
659,
63,
1264
]
],
[
[
1570,
25,
1250
],
[
1250,
63,
1264
]
],
[
[
1570,
40,
1056
],
[
1056,
24,
1264
]
],
[
[
1570,
25,
1011
],
[
1011,
64,
1264
]
]
] | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
],
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
]
] | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Azithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Azithromycin (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Doxepin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Azithromycin may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Azithromycin (Compound) resembles Telithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Azithromycin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Doxepin |
DB06595 | DB06655 | 1,491 | 5 | [
"DDInter1214",
"DDInter1077"
] | Midostaurin | Liraglutide | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
1491,
24,
5
]
],
[
[
1491,
63,
353
],
[
353,
23,
5
]
],
[
[
1491,
64,
915
],
[
915,
24,
5
]
],
[
[
1491,
63,
245
],
[
245,
24,
5
]
],
[
[
1491,
24,
1296
],
[
1296,
63,
5
]
],
[
[
1491,
25,
1154
],
[
1154,
63,
5
]
],
[
[
1491,
63,
1101
],
[
1101,
25,
5
]
],
[
[
1491,
64,
246
],
[
246,
25,
5
]
],
[
[
1491,
63,
353
],
[
353,
24,
700
],
[
700,
23,
5
]
],
[
[
1491,
63,
1252
],
[
1252,
24,
870
],
[
870,
24,
5
]
]
] | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
]
] | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Midostaurin may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Midostaurin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Liraglutide
Midostaurin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide |
DB00816 | DB06402 | 1,674 | 1,079 | [
"DDInter1346",
"DDInter1756"
] | Orciprenaline | Telavancin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Moderate | 1 | [
[
[
1674,
24,
1079
]
],
[
[
1674,
21,
28750
],
[
28750,
60,
1079
]
],
[
[
1674,
63,
1181
],
[
1181,
24,
1079
]
],
[
[
1674,
24,
124
],
[
124,
63,
1079
]
],
[
[
1674,
24,
1520
],
[
1520,
24,
1079
]
],
[
[
1674,
35,
1148
],
[
1148,
24,
1079
]
],
[
[
1674,
25,
868
],
[
868,
64,
1079
]
],
[
[
1674,
64,
1166
],
[
1166,
25,
1079
]
],
[
[
1674,
24,
1011
],
[
1011,
64,
1079
]
],
[
[
1674,
25,
478
],
[
478,
25,
1079
]
]
] | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
]
] | Orciprenaline (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Telavancin (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Orciprenaline may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Telavancin
Orciprenaline may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Telavancin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Telavancin
Orciprenaline may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Telavancin |
DB00468 | DB00607 | 1,424 | 1,249 | [
"DDInter1557",
"DDInter1256"
] | Quinine | Nafcillin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections . | Moderate | 1 | [
[
[
1424,
24,
1249
]
],
[
[
1424,
6,
7950
],
[
7950,
45,
1249
]
],
[
[
1424,
21,
28792
],
[
28792,
60,
1249
]
],
[
[
1424,
63,
1101
],
[
1101,
23,
1249
]
],
[
[
1424,
25,
609
],
[
609,
62,
1249
]
],
[
[
1424,
25,
351
],
[
351,
63,
1249
]
],
[
[
1424,
24,
1320
],
[
1320,
63,
1249
]
],
[
[
1424,
63,
79
],
[
79,
24,
1249
]
],
[
[
1424,
23,
1620
],
[
1620,
63,
1249
]
],
[
[
1424,
62,
964
],
[
964,
24,
1249
]
]
] | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
]
]
] | Quinine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nafcillin (Compound)
Quinine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Nafcillin
Quinine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Nafcillin
Quinine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin |
DB00585 | DB06616 | 1,127 | 594 | [
"DDInter1309",
"DDInter224"
] | Nizatidine | Bosutinib | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
1127,
24,
594
]
],
[
[
1127,
63,
883
],
[
883,
1,
594
]
],
[
[
1127,
18,
2065
],
[
2065,
45,
594
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
594
]
],
[
[
1127,
18,
3769
],
[
3769,
46,
594
]
],
[
[
1127,
18,
2801
],
[
2801,
57,
594
]
],
[
[
1127,
21,
28709
],
[
28709,
60,
594
]
],
[
[
1127,
23,
460
],
[
460,
63,
594
]
],
[
[
1127,
25,
786
],
[
786,
63,
594
]
],
[
[
1127,
24,
1519
],
[
1519,
63,
594
]
]
] | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) downregulates {v} (Gene)",
"SRC"
],
[
"SRC",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) downregulates {v} (Gene)",
"EBP"
],
[
"EBP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
],
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
]
] | Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Nizatidine (Compound) downregulates SRC (Gene) and SRC (Gene) is bound by Bosutinib (Compound)
Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Bosutinib (Compound)
Nizatidine (Compound) downregulates EBP (Gene) and EBP (Gene) is upregulated by Bosutinib (Compound)
Nizatidine (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Bosutinib (Compound)
Nizatidine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may lead to a major life threatening interaction when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir and Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00404 | DB08865 | 523 | 1,593 | [
"DDInter54",
"DDInter448"
] | Alprazolam | Crizotinib | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
523,
24,
1593
]
],
[
[
523,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
523,
18,
2942
],
[
2942,
46,
1593
]
],
[
[
523,
7,
5137
],
[
5137,
46,
1593
]
],
[
[
523,
18,
10375
],
[
10375,
57,
1593
]
],
[
[
523,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
523,
24,
283
],
[
283,
62,
1593
]
],
[
[
523,
1,
1418
],
[
1418,
24,
1593
]
],
[
[
523,
23,
286
],
[
286,
63,
1593
]
],
[
[
523,
24,
375
],
[
375,
63,
1593
]
]
] | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) downregulates {v} (Gene)",
"KEAP1"
],
[
"KEAP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) upregulates {v} (Gene)",
"KDM5A"
],
[
"KDM5A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
]
] | Alprazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Alprazolam (Compound) downregulates KEAP1 (Gene) and KEAP1 (Gene) is upregulated by Crizotinib (Compound)
Alprazolam (Compound) upregulates KDM5A (Gene) and KDM5A (Gene) is upregulated by Crizotinib (Compound)
Alprazolam (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Crizotinib (Compound)
Alprazolam (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Alprazolam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Alprazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB00055 | DB00215 | 834 | 1,230 | [
"DDInter605",
"DDInter388"
] | Drotrecogin alfa | Citalopram | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Moderate | 1 | [
[
[
834,
24,
1230
]
],
[
[
834,
24,
318
],
[
318,
40,
1230
]
],
[
[
834,
25,
500
],
[
500,
63,
1230
]
],
[
[
834,
64,
582
],
[
582,
24,
1230
]
],
[
[
834,
25,
1167
],
[
1167,
24,
1230
]
],
[
[
834,
24,
121
],
[
121,
64,
1230
]
],
[
[
834,
25,
1618
],
[
1618,
64,
1230
]
],
[
[
834,
25,
1018
],
[
1018,
25,
1230
]
],
[
[
834,
24,
318
],
[
318,
6,
5744
],
[
5744,
45,
1230
]
],
[
[
834,
25,
500
],
[
500,
63,
318
],
[
318,
40,
1230
]
]
] | [
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} (Compound) resembles {v} (Compound)",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptokinase"
],
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"HTR2C"
],
[
"HTR2C",
"{u} (Gene) is bound by {v} (Compound)",
"Citalopram"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} (Compound) resembles {v} (Compound)",
"Citalopram"
]
]
] | Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Streptokinase and Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Citalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Citalopram
Drotrecogin alfa may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Citalopram
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) binds HTR2C (Gene) and HTR2C (Gene) is bound by Citalopram (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound) |
DB09268 | DB11796 | 1,662 | 1,612 | [
"DDInter1464",
"DDInter786"
] | Picosulfuric acid | Fostemsavir | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments. | Moderate | 1 | [
[
[
1662,
24,
1612
]
],
[
[
1662,
63,
1220
],
[
1220,
23,
1612
]
],
[
[
1662,
64,
1424
],
[
1424,
24,
1612
]
],
[
[
1662,
24,
823
],
[
823,
63,
1612
]
],
[
[
1662,
63,
1264
],
[
1264,
24,
1612
]
],
[
[
1662,
24,
927
],
[
927,
24,
1612
]
],
[
[
1662,
24,
351
],
[
351,
25,
1612
]
],
[
[
1662,
24,
877
],
[
877,
64,
1612
]
],
[
[
1662,
63,
1487
],
[
1487,
25,
1612
]
],
[
[
1662,
64,
39
],
[
39,
25,
1612
]
]
] | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
]
] | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Picosulfuric acid may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Fostemsavir
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Fostemsavir
Picosulfuric acid may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Fostemsavir |
DB00317 | DB12825 | 883 | 1,375 | [
"DDInter810",
"DDInter1032"
] | Gefitinib | Lefamulin | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
883,
24,
1375
]
],
[
[
883,
24,
159
],
[
159,
63,
1375
]
],
[
[
883,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
883,
24,
98
],
[
98,
24,
1375
]
],
[
[
883,
40,
1195
],
[
1195,
24,
1375
]
],
[
[
883,
40,
1069
],
[
1069,
25,
1375
]
],
[
[
883,
24,
609
],
[
609,
25,
1375
]
],
[
[
883,
1,
594
],
[
594,
25,
1375
]
],
[
[
883,
63,
600
],
[
600,
25,
1375
]
],
[
[
883,
35,
392
],
[
392,
25,
1375
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Gefitinib (Compound) resembles Erlotinib (Compound) and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Gefitinib (Compound) resembles Vandetanib (Compound) and Vandetanib may lead to a major life threatening interaction when taken with Lefamulin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
Gefitinib (Compound) resembles Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Lefamulin
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Lefamulin
Gefitinib (Compound) resembles Lapatinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Lefamulin |
DB00877 | DB06402 | 629 | 1,079 | [
"DDInter1678",
"DDInter1756"
] | Sirolimus | Telavancin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others. | Major | 2 | [
[
[
629,
25,
1079
]
],
[
[
629,
64,
91
],
[
91,
1,
1079
]
],
[
[
629,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
629,
63,
1181
],
[
1181,
24,
1079
]
],
[
[
629,
24,
124
],
[
124,
63,
1079
]
],
[
[
629,
24,
477
],
[
477,
24,
1079
]
],
[
[
629,
64,
485
],
[
485,
24,
1079
]
],
[
[
629,
25,
913
],
[
913,
63,
1079
]
],
[
[
629,
25,
609
],
[
609,
24,
1079
]
],
[
[
629,
24,
868
],
[
868,
64,
1079
]
]
] | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} (Compound) resembles {v} (Compound)",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
]
] | Sirolimus may lead to a major life threatening interaction when taken with Vancomycin and Vancomycin (Compound) resembles Telavancin (Compound)
Sirolimus (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Telavancin |
DB00445 | DB00529 | 322 | 789 | [
"DDInter655",
"DDInter779"
] | Epirubicin | Foscarnet | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Moderate | 1 | [
[
[
322,
24,
789
]
],
[
[
322,
21,
28965
],
[
28965,
60,
789
]
],
[
[
322,
23,
112
],
[
112,
62,
789
]
],
[
[
322,
63,
1494
],
[
1494,
24,
789
]
],
[
[
322,
25,
770
],
[
770,
63,
789
]
],
[
[
322,
24,
372
],
[
372,
63,
789
]
],
[
[
322,
24,
1555
],
[
1555,
24,
789
]
],
[
[
322,
35,
77
],
[
77,
63,
789
]
],
[
[
322,
25,
877
],
[
877,
64,
789
]
],
[
[
322,
24,
593
],
[
593,
64,
789
]
]
] | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Blood urea increased"
],
[
"Blood urea increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
]
]
] | Epirubicin (Compound) causes Blood urea increased (Side Effect) and Blood urea increased (Side Effect) is caused by Foscarnet (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Foscarnet
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Epirubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Epirubicin (Compound) resembles Idarubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet
Epirubicin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Foscarnet
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Foscarnet |
DB00562 | DB01105 | 1,014 | 222 | [
"DDInter188",
"DDInter1665"
] | Benzthiazide | Sibutramine | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Moderate | 1 | [
[
[
1014,
24,
222
]
],
[
[
1014,
24,
659
],
[
659,
63,
222
]
],
[
[
1014,
63,
176
],
[
176,
24,
222
]
],
[
[
1014,
24,
1144
],
[
1144,
24,
222
]
],
[
[
1014,
23,
126
],
[
126,
24,
222
]
],
[
[
1014,
40,
178
],
[
178,
63,
222
]
],
[
[
1014,
1,
811
],
[
811,
24,
222
]
],
[
[
1014,
40,
674
],
[
674,
24,
222
]
],
[
[
1014,
24,
1053
],
[
1053,
64,
222
]
],
[
[
1014,
25,
1166
],
[
1166,
25,
222
]
]
] | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Benzthiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
]
] | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Sibutramine
Benzthiazide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Sibutramine |
DB06212 | DB08912 | 165 | 1,040 | [
"DDInter1833",
"DDInter462"
] | Tolvaptan | Dabrafenib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
165,
24,
1040
]
],
[
[
165,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
165,
21,
28779
],
[
28779,
60,
1040
]
],
[
[
165,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
165,
63,
478
],
[
478,
24,
1040
]
],
[
[
165,
23,
466
],
[
466,
63,
1040
]
],
[
[
165,
24,
1478
],
[
1478,
24,
1040
]
],
[
[
165,
25,
129
],
[
129,
24,
1040
]
],
[
[
165,
25,
384
],
[
384,
63,
1040
]
],
[
[
165,
40,
1080
],
[
1080,
24,
1040
]
]
] | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Tolvaptan",
"{u} (Compound) resembles {v} (Compound)",
"Conivaptan"
],
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
]
] | Tolvaptan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Tolvaptan (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Dabrafenib (Compound)
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolvaptan may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolvaptan may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Tolvaptan (Compound) resembles Conivaptan (Compound) and Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib |
DB01030 | DB11003 | 869 | 748 | [
"DDInter1835",
"DDInter100"
] | Topotecan | Anthrax vaccine | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
869,
24,
748
]
],
[
[
869,
63,
322
],
[
322,
24,
748
]
],
[
[
869,
24,
594
],
[
594,
24,
748
]
],
[
[
869,
24,
564
],
[
564,
63,
748
]
],
[
[
869,
25,
676
],
[
676,
63,
748
]
],
[
[
869,
64,
1057
],
[
1057,
24,
748
]
],
[
[
869,
25,
1011
],
[
1011,
24,
748
]
],
[
[
869,
63,
322
],
[
322,
63,
168
],
[
168,
24,
748
]
],
[
[
869,
63,
168
],
[
168,
24,
322
],
[
322,
24,
748
]
],
[
[
869,
24,
594
],
[
594,
25,
676
],
[
676,
63,
748
]
]
] | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
],
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.